

# BMJ Open

## Postoperative Decrease of Serum Albumin is an Early Predictor of Complications After Major Abdominal Surgery: A Prospective Cohort Study

|                                 |  |
|---------------------------------|--|
| Journal:                        | <i>BMJ Open</i>  |
| Manuscript ID                   | bmjopen-2016-013966  |
| Article Type:                   | Research   |
| Date Submitted by the Author:   | 25-Aug-2016  |
| Complete List of Authors:       | Labgaa, Ismail; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Joliat, Gaëtan-Romain ; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Kefleyesus, Amanuel; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Mantziari, Styliani; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Schäfer, Markus; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Demartines, Nicolas; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>HUBNER, Martin; University Hospital of Lausanne (CHUV), Department of Visceral Surgery |
| <b>Primary Subject Heading</b>: | Surgery  |
| Secondary Subject Heading:      | Surgery  |
| Keywords:                       | Biomarker, albumin, major surgery, postoperative complications, stress response  |
|                                 |  |

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

*Research Article*

**Postoperative Decrease of Serum Albumin is an Early Predictor of Complications After Major Abdominal Surgery: A Prospective Cohort Study**

Ismail Labgaa<sup>1\*</sup>, Gaëtan-Romain Joliat<sup>1\*</sup>, Amanuel Kefleyesus<sup>1</sup>, Styliani Mantziari<sup>1</sup>, Markus Schäfer<sup>1</sup>, Nicolas Demartines<sup>1</sup>, Martin Hübner<sup>1</sup>

<sup>1</sup> Department of Visceral Surgery, University Hospital of Lausanne (CHUV), Switzerland

\* Equal contribution

**Corresponding author:**

Nicolas Demartines, MD, FACS, FRCS

Professor and Chairman

Department of visceral surgery

University Hospital CHUV

1011 Lausanne, Switzerland

Phone: +41 21 314 24 00 / Fax: +41 21 314 24 11

E-mail: [demartines@chuv.ch](mailto:demartines@chuv.ch)

The present study was presented at the 103<sup>rd</sup> Congress of Swiss Surgery (June 2016, Lugano, Switzerland) and will be presented at the Clinical Congress of the American College of Surgeons (October 2016, Washington, DC, USA).

**Key words:** Biomarker; albumin; major surgery; postoperative complications; stress response

**Word count:** 3106

## ABSTRACT

**Objective:** To test postoperative serum albumin drop ( $\Delta$ Alb) as a marker of surgical stress response and early predictor of clinical outcomes.

**Design:** Prospective cohort study (NCT02356484). Albumin was prospectively measured in 138 patients undergoing major abdominal surgery. Blood samples were collected before surgery and on postoperative days 0, 1, 2, and 3.  $\Delta$ Alb was compared to the *Modified Estimation of Physiologic Ability and Surgical Stress* (mE-PASS) score and correlated to the performances of C-reactive protein (CRP), procalcitonin (PCT), and lactate (LCT). Postoperative outcomes were postoperative complications according to both Clavien classification and Comprehensive Complication Index (CCI), and length of hospital stay (LoS).

**Setting:** Division of abdominal surgery in a European tertiary center.

**Participants:** Adult patients undergoing elective major abdominal surgery, with a duration  $\geq 2$ h. Patients on immunosuppressive or antibiotic treatments before surgery were excluded.

**Results:** The level of serum albumin rapidly dropped after surgery.  $\Delta$ Alb correlated to the mE-PASS score ( $r=0.275$ ,  $p=0.01$ ) and to CRP increase ( $r=0.536$ ,  $p<0.001$ ).  $\Delta$ Alb also correlated to overall complications ( $r=0.485$ ,  $p<0.001$ ), CCI ( $r=0.383$ ,  $p<0.001$ ) and LoS ( $r=0.468$ ,  $p<0.001$ ). A  $\Delta$ Alb  $\geq 10$  g/L yielded a sensitivity of 77.1% and a specificity of 67.2% (AUC: 78.3%) to predict complications. Patients with  $\Delta$ Alb  $\geq 10$ g/l on POD 1 showed a 3 fold increased risk of overall postoperative complications.

**Conclusion:**  $\Delta$ Alb correlated to the extent of surgery and to other biological stress markers.  $\Delta$ Alb  $\geq 10$  g/L on POD 1 appears to be a promising early predictor of postoperative complications.

## STRENGTHS AND LIMITATIONS OF THE STUDY

- The present study has a prospective design and offers a head-to-head comparison with biomarkers currently used in clinical practice (C-Reactive Protein and Procalcitonin).
- Albumin drop was thoroughly assessed by analyzing its correlation with a comprehensive panel of surrogate markers for surgical trauma and validated scores for outcomes.
- Serum albumin is a biomarker with ideal properties for this setting: easy to measure and to interpret, readily available, early modified after surgery, can be repeated for monitoring, and associated with low costs.
- This study involved a single center and included a training cohort, without validation cohort.

## INTRODUCTION

Abdominal surgery is among the most frequently performed elective surgery<sup>1</sup>. Although surgical and perioperative improvements reduced postoperative mortality over the last decades, postoperative morbidity has remained high<sup>2</sup>. Postoperative complications cause a substantial financial burden, while the current context stresses the urgency to contain health care expenditures<sup>2</sup>.

The magnitude of metabolic stress response recapitulates the extent of surgery<sup>3,4</sup> and presumably contributes to the risk of developing postoperative complications<sup>5,6</sup>. Early identification of patients at risk may improve outcomes, since measures to attenuate the overshooting surgical stress response and to reduce morbidity exist<sup>7</sup>.

Although C-reactive protein (CRP) and procalcitonin (PCT) have been suggested as predictors for adverse outcomes in colorectal surgery, they both display the critical limitation of a slow kinetics<sup>8,9</sup>. Serum albumin (Alb) is an acute phase protein with immediate response to metabolic stress<sup>3,10</sup>. Preliminary data suggested that Alb level rapidly dropped after surgery and correlated to outcomes in esophageal<sup>11</sup>, oral cancer<sup>12</sup>, abdominal<sup>3</sup>, pancreatic<sup>13</sup>, liver resection<sup>14</sup>/transplant<sup>15</sup> and cardiac<sup>16</sup> surgeries. However, prospective validation is missing and Alb is not used to assess surgical stress or to predict outcomes.

This study aimed to test the hypotheses that early postoperative albumin drop (I) reflects the magnitude of surgical trauma, (II) correlates to established markers of metabolic stress, and (III) predicts postoperative complications.

## METHODS

### Study design and patient groups

This prospective study was conducted at the Department of Visceral Surgery of the University Hospital of Lausanne Switzerland (CHUV) between February and December 2015 (NCT02356484). The study was approved by the Institutional Review Board (N°367/15) and all patients provided written consent prior to surgery. Inclusion criteria were age >18 years, and elective major abdominal surgery - defined as an operative procedure with duration  $\geq 2$ h<sup>17</sup>, whereas patients on immunosuppressive or antibiotic treatments before surgery were excluded.

Demographics, comorbidities, surgical details and clinical outcomes were prospectively collected and anonymized in a computerized protected database. The sample size was similar to comparable studies in the field<sup>18</sup>.

### Extent of surgery

The amplitude of surgical stress was measured by the *Modified Estimation of Physiologic Ability and Surgical Stress* (mE-PASS). Briefly, mE-PASS score encompasses 7 items (6 preoperative variables and the surgical procedure). It predicts the in-hospital mortality and the 30-day mortality rates, respectively<sup>19</sup>. Type of surgery, operative time, and surgical approach (open vs. laparoscopic) were recorded. Conversions from laparoscopy to laparotomy were counted as laparoscopic cases. Anesthesiologists and surgeons jointly estimated blood loss by measuring the volume of aspirated fluid and soaked gauzes.

### Biological markers

Serum levels of albumin, CRP, PCT and lactate (LCT) were perioperatively measured in a fasting state, following standardized institutional guidelines. Blood samples were drawn the day before surgery, the day of surgery (4-6 hours after the end of the operation) and on the first, second and third postoperative day. As baseline values tend to show large variations especially for

albumin<sup>3 10</sup>, we considered that a dynamic value (difference between two time-points) might be more informative than a snapshot value. Several values based on pre- and post-operative concentrations, were thus calculated for each marker (i.e.,  $\Delta$  Max: Maximal difference between the pre- and post-operative values;  $\Delta$  POD 0: Difference of concentration on POD -1 and POD 0;  $\Delta$  POD 1: Difference of concentration on POD -1 and POD 1).

### Outcome measures

Complications were graded with the Clavien classification within 30 postoperative days, accounting grade I/II events as minor complications and grade III-V as major complications<sup>20</sup>. Every complication was documented. Global morbidity for each patient was quantified by the Comprehensive Complication Index (CCI) on a scale from 0 to 100<sup>21</sup>. Length of stay (LoS) was considered as the duration from the day of surgery until discharge.

### Statistical analysis

Continuous variables were presented as mean with standard deviation (SD) or median value with interquartile range (IQR) depending on the normality of the distribution and compared using Student's *t* test and Mann-Whitney U test, whereas categorical variables were given as frequencies with percentages and compared with chi-square test. For statistical analyses, the following parameters were dichotomized: age (>60 years), body-mass index (>25 kg/m<sup>2</sup>), operative time (>180 minutes), and blood loss (>200 ml). Spearman's and Pearson's tests were used to measure correlations of categorical and continuous variables, respectively. Receiver operating characteristic (ROC) curves were applied to obtain the area under the curve (AUC), and to determine ideal cut-offs. Logistic regression was applied to identify independent predictors; variables with significance < 0.1 were included in multivariable analyses. A *p* value <0.05 was considered to be statistically significant in all tests. Data analyses were generated using SPSS v20 statistical software (Chicago, IL).

## RESULTS

### Patients Characteristics, Details of Surgery, and Outcomes

During the study period, 155 consecutive patients undergoing major abdominal surgery were potentially eligible for inclusion, but 17 of them refused to participate. As a result, 138 patients were included in the study and had a complete follow-up. Demographics and surgical details are displayed in **Table 1**. Median mE-PASS score was 0.66 (IQR 0.45-0.96).

Overall, 60/138 patients (43%) experienced at least one complication, and one patient died after total gastrectomy and splenopancreatectomy due to cardiorespiratory arrest. Minor and major complications were observed in 35 and 25 patients, respectively. Patients showed a mean CCI of 13.2 (SD 18.5), and were discharged after a median LoS of 8 days (IQR 5-15 days).

### Perioperative Profile of Biomarkers

The perioperative profile of albumin showed a rapid drop induced by surgery, followed by a plateau phase between POD 0 and POD 3 (**Supplementary Figure 1**). Lactate levels peaked in the first 4-6h after surgery and were back to baseline on POD1. Conversely, CRP and PCT showed slow kinetics reaching maximal values on POD 4 and 3, respectively. The mean maximal decrease of albumin was 11.3 g/L ( $\pm$  5.6), which was similar to albumin drop on POD 1: 10.1 g/L (SD: 5.8). Further analyses were hence focused on  $\Delta$ Alb on POD1.

### Correlation of $\Delta$ Alb to surgical stress, biomarkers, and outcomes

$\Delta$ Alb on POD1 correlated to surgical stress (mE-PASS) ( $r=0.275$ ,  $p=0.01$ ) and to surrogates such as duration of surgery ( $r=0.562$ ,  $p<0.001$ ), blood loss ( $r=0.391$ ,  $p<0.001$ ), and surgical approach ( $\rho=0.55$ ,  $p<0.001$ ) (**Figure 1**).

$\Delta$ Alb on POD1 also correlated to maximal increases of CRP ( $r=0.54$ ,  $p<0.001$ ), PCT ( $r=0.43$ ,  $p<0.001$ ), and LCT ( $r=0.25$ ,  $p=0.02$ ). Furthermore, a positive and significant correlation was highlighted between  $\Delta$ Alb on POD1 and  $\Delta$ CRP on POD4 ( $\rho=0.234$ ,  $p=0.044$ ).  $\Delta$ Alb on POD1 was



1 significantly associated with adverse outcomes, showing significant correlations with CCI  
2  
3  
4 ( $\rho=0.383$ ,  $p<0.001$ ) and LoS ( $\rho=0.468$ ,  $p<0.001$ ) (**Figure 2**).

5  
6 The correlations of CRP, PCT, and LCT with surgical stress and outcomes were also tested and are  
7  
8 detailed in **Supplementary Table 1**.

### 13 **Predictive Value of Albumin Decrease**

14  
15 A ROC curve was used to determine the optimal cut-off of  $\Delta\text{Alb}$  on POD1, settled at 10  
16  
17 g/L. The area under the curve (AUC) measured 78.3% (95% CI: 70-87%), giving a sensitivity of  
18  
19 77.1%, a specificity of 67.2%, a positive predictive value of 64.8%, and a negative predictive value  
20  
21 of 79.6%, for overall complications (**Figure 3**). The respective ROC curves for POD1 values of  
22  
23  $\Delta\text{CRP}$ ,  $\Delta\text{PCT}$ , and  $\Delta\text{LCT}$  are provided in **Supplementary Figure 2**.

24  
25 It was subsequently investigated whether this cut-off was able to discriminate and stratify patients'  
26  
27 risk. Patients with an intense drop of Alb on POD 1 ( $\Delta\text{Alb POD1} \geq 10$  g/L) showed a higher mE-  
28  
29 PASS (0.73 vs. 0.49,  $p=0.029$ ) with higher rates of minor (36% vs. 15%,  $p=0.011$ ), major (28% vs.  
30  
31 6%,  $p=0.002$ ), and overall complications (64% vs. 20%,  $p<0.001$ ). This resulted in a significantly  
32  
33 higher CCI (20.9 vs. 0,  $p<0.001$ ) and in a significantly longer LoS (13 vs. 4 days,  $p<0.001$ )  
34  
35 (**Supplementary Table 2**).

36  
37 Logistic regression with multivariable analysis identified open surgery (OR: 11.22; 95% IC: 2.74-  
38  
39 46.05;  $p=0.001$ ) and  $\Delta\text{Alb POD1} \geq 10$  g/L (OR: 3.29; 95% CI: 1.14-9.49;  $p=0.028$ ) to be  
40  
41  
42  
43  
44  
45 independently associated with overall complications (**Table 2**).

## DISCUSSION

Surgery induced a rapid decrease of serum albumin in patients undergoing elective major abdominal procedures; and it remained stable for several postoperative days. The decrease in serum albumin correlated with (I) the extent of surgery (mE-PASS, blood loss, duration of surgery, and surgical approach), (II) the maximal amplitude of other stress markers, such as CRP, PCT and LCT and (III) was consistently associated with adverse outcomes (according to both Clavien classification, CCI, and LoS). A serum albumin decrease  $\geq 10$  g/L on POD 1 was independently associated with a 3-fold increased risk for postoperative complication.

The present study tested a panel of 4 biomarkers of which 2 are routinely used and served as benchmarks (CRP and PCT) and 2 are less established markers and deserved prospective investigations (Alb and LCT). The mE-PASS accurately recapitulates surgical stress, and was validated and used in abdominal surgery<sup>19,22-25</sup>. To our knowledge, there is no other validated and available score. One study endpoint was the CCI, which is a score summing each complication graded according to the Clavien classification. As a result, CCI avoids omitting minor complications, and is therefore more accurate than the Clavien classification alone<sup>21</sup>. Serum albumin showed the more consistent correlation with stress response and clinical outcomes. Alb and LCT both display some of the features for ideal markers: easy to measure and to interpret, readily available, can be repeated for monitoring and non-expensive. While Alb rapidly dropped after surgery and subsequently stabilized until POD 3, lactate showed a prompt increase followed by a fast return to baseline value, already on POD 1. It can be assumed that the timing of blood collection may have a more important impact on LCT than on Alb. As a consequence, Alb is more robust and easier to use in the clinical setting. Importantly, the selected markers were repeatedly measured, which allowed to capture their perioperative profiles and to further calculated differences of concentrations between various time-points. The latter was revealed to be pivotal and more informative than a single value.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Some limitations need to be addressed. The present analyses were focused on 4 markers that are readily available and easy to evaluate in clinical setting. This non-inclusive panel of markers could be perceived as a methodological shortcoming. Notwithstanding, integrating complex and costly markers such as cytokines would also be of clinically restraint relevance, given their low reproducibility, cost and complexity. In addition, blood collection on POD 0 typically occurred 4-6 hours after the end of surgery, which raises 2 concerns: (I) because of the variety of different postoperative scenarios (i.e. patients transferred to: ICU, intermediate care, ward, or staying in recovery room), any potential variability from the protocol cannot be excluded, and (II) it may also be argued that this delay is long enough to alter the discriminatory ability of certain markers, particularly lactate <sup>26</sup>.

Available data on the predictive role of postoperative Alb are scarce; and most of these reports were retrospective studies <sup>11-13 15 16</sup>. Of note, each of the studies investigated only a single postoperative value of serum albumin. This represents a critical drawback as it cannot be discriminated whether the low postoperative concentration of serum albumin resulted from intense surgical stress or from low preoperative level, which is an acknowledged predictor of increased postoperative complication <sup>27 28</sup>. A prospective pilot study in abdominal surgery – conducted recently in our institution- showed consistent findings, with an increased risk of complication related to the amplitude of serum albumin postoperative drop <sup>3</sup>. Of note, the cohorts from this previous study (70 patients) and from the present one (138 patients) were strictly distinct. Postoperative lactate has been more thoroughly explored in liver surgery, with few reports in other surgical fields. In a recent landmark study, Vibert et al. demonstrated that a postoperative cut-off of arterial lactate > 3mmol/L at the end of surgery was an independent predictor of complications after elective hepatectomies <sup>26</sup>. Their conclusion correlates with the present findings since  $\Delta$ LCT POD0 was correlated with mE-PASS (p=0.039), overall complication (p<0.001), CCI (p=0.007) and LoS (p=0.008) (**Figure 2**). Although both CRP and PCT are routinely used markers in clinical practice, they are typically contributive on POD 4 only. The present study design allowed to

1  
2 confirm the ultimate advantage of Alb to be up-regulated within the early postoperative phase,  
3  
4 illustrated by the correlation between  $\Delta$ Alb on POD1 and  $\Delta$ CRP on POD4 ( $p=0.234$ ,  $p=0.044$ ),  
5  
6 highlighted in this study. In fact,  $\Delta$ Alb on POD1 was even more performant than  $\Delta$ CRP on POD4,  
7  
8 illustrated by AUC of 0.78 and 0.75, respectively (Figure 3 and Supplementary 3D). Other  
9  
10 candidate biomarkers have been explored to predict postoperative complications. Recently, Rettig  
11  
12 et al. tested the predictive performance of IL-6 in a prospective cohort of 137 patients undergoing  
13  
14 elective abdominal surgery<sup>18</sup>. Although a high level of IL-6 on POD1 was associated with  
15  
16 increased risk of complication, one must consider its intrinsic limitations, such as high costs,  
17  
18 precluding its routine use in clinical practice<sup>29</sup>. Furthermore, IL-6 on POD1 yielded an AUC of  
19  
20 0.67 while the present AUC of Alb on POD 1 reached 0.78.  
21  
22  
23

24 How the monitoring of Alb in surgical patients can lead to better outcomes is key question.  
25  
26 Measures to preoperatively attenuate the overshooting stress response to surgery have been  
27  
28 extensively explored. Interestingly, successful attempts were reported with immunonutrition<sup>30</sup>,  
29  
30 enhanced recovery programs (ERAS)<sup>31 32</sup>, or high-dose glucocorticoids<sup>33</sup>. Whether these options  
31  
32 would be able to restrain the stress response, once triggered, in the early postoperative phase  
33  
34 remains to be investigated. In this setting, albumin drop may facilitate to test whether these  
35  
36 measures may also be beneficial in the early postoperative phase, by permitting to design clinical  
37  
38 trials enriched for patients at higher risk.  
39  
40  
41

42 In summary, early postoperative decrease of serum albumin correlated with the (I)  
43  
44 extent of surgery, (II) its metabolic response, and with (III) adverse outcomes such as  
45  
46 complications and length of hospital stay.  
47  
48

49 A decreased concentration of serum albumin  $\geq 10$ g/l on POD 1 was associated with a 3-fold  
50  
51 increased risk of overall postoperative complications; albumin decrease occurs rapidly after  
52  
53 surgery, remains stable for several days. As it is easy to measure, it could be used to identify  
54  
55 patients at risk.  
56  
57  
58  
59  
60

**REFERENCES**

1. Noordzij PG, Poldermans D, Schouten O, et al. Postoperative mortality in The Netherlands: a population-based analysis of surgery-specific risk in adults. *Anesthesiology* 2010;**112**(5):1105-15.
2. Vonlanthen R, Slankamenac K, Breitenstein S, et al. The impact of complications on costs of major surgical procedures: a cost analysis of 1200 patients. *Ann Surg* 2011;**254**(6):907-13.
3. Mantziari S, Hubner M, Coti-Bertrand P, et al. A Novel Approach to Major Surgery: Tracking Its Pathophysiologic Footprints. *World J Surg* 2015.
4. Thorell A, Nygren J, Ljungqvist O. Insulin resistance: a marker of surgical stress. *Curr Opin Clin Nutr Metab Care* 1999;**2**(1):69-78.
5. Kohl BA, Deutschman CS. The inflammatory response to surgery and trauma. *Curr Opin Crit Care* 2006;**12**(4):325-32.
6. Amar D, Zhang H, Park B, et al. Inflammation and outcome after general thoracic surgery. *Eur J Cardiothorac Surg* 2007;**32**(3):431-4.
7. Hall R. Identification of inflammatory mediators and their modulation by strategies for the management of the systemic inflammatory response during cardiac surgery. *J Cardiothorac Vasc Anesth* 2013;**27**(5):983-1033.
8. Facy O, Paquette B, Orry D, et al. Diagnostic Accuracy of Inflammatory Markers As Early Predictors of Infection After Elective Colorectal Surgery: Results From the IMACORS Study. *Ann Surg* 2015.
9. Giaccaglia V, Salvi PF, Antonelli MS, et al. Procalcitonin Reveals Early Dehiscence in Colorectal Surgery: The PREDICS Study. *Ann Surg* 2015.
10. Hubner M, Mantziari S, Demartines N, et al. Postoperative Albumin Drop Is a Marker for Surgical Stress and a Predictor for Clinical Outcome: A Pilot Study. *Gastroenterol Res Pract* 2016;**2016**:8743187.

11. Ryan AM, Hearty A, Prichard RS, et al. Association of hypoalbuminemia on the first postoperative day and complications following esophagectomy. *J Gastrointest Surg* 2007;**11**(10):1355-60.
12. Lee JI, Kwon M, Roh JL, et al. Postoperative hypoalbuminemia as a risk factor for surgical site infection after oral cancer surgery. *Oral Dis* 2015;**21**(2):178-84.
13. Fujiwara Y, Shiba H, Shirai Y, et al. Perioperative serum albumin correlates with postoperative pancreatic fistula after pancreaticoduodenectomy. *Anticancer Res* 2015;**35**(1):499-503.
14. Labgaa I, Joliat GR, Demartines N, et al. Serum albumin is an early predictor of complications after liver surgery. *Dig Liver Dis* 2016.
15. Sang BH, Bang JY, Song JG, et al. Hypoalbuminemia Within Two Postoperative Days Is an Independent Risk Factor for Acute Kidney Injury Following Living Donor Liver Transplantation: A Propensity Score Analysis of 998 Consecutive Patients. *Crit Care Med* 2015.
16. Lee EH, Chin JH, Choi DK, et al. Postoperative hypoalbuminemia is associated with outcome in patients undergoing off-pump coronary artery bypass graft surgery. *J Cardiothorac Vasc Anesth* 2011;**25**(3):462-8.
17. Hubner M, Cerantola Y, Grass F, et al. Preoperative immunonutrition in patients at nutritional risk: results of a double-blinded randomized clinical trial. *Eur J Clin Nutr* 2012;**66**(7):850-5.
18. Rettig TC, Verwijmeren L, Dijkstra IM, et al. Postoperative Interleukin-6 Level and Early Detection of Complications After Elective Major Abdominal Surgery. *Ann Surg* 2015.
19. Haga Y, Ikejiri K, Wada Y, et al. A multicenter prospective study of surgical audit systems. *Ann Surg* 2011;**253**(1):194-201.
20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;**240**(2):205-13.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
21. Slankamenac K, Graf R, Barkun J, et al. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. *Ann Surg* 2013;**258**(1):1-7.
  22. Haga Y, Ikejiri K, Takeuchi H, et al. Value of general surgical risk models for predicting postoperative liver failure and mortality following liver surgery. *J Surg Oncol* 2012;**106**(7):898-904.
  23. Haga Y, Wada Y, Takeuchi H, et al. Evaluation of modified Estimation of Physiologic Ability and Surgical Stress in gastric carcinoma surgery. *Gastric Cancer* 2012;**15**(1):7-14.
  24. Haga Y, Wada Y, Takeuchi H, et al. Evaluation of modified estimation of physiologic ability and surgical stress in patients undergoing surgery for choledochocystolithiasis. *World J Surg* 2014;**38**(5):1177-83.
  25. Haga Y, Wada Y, Saitoh T, et al. Value of general surgical risk models for predicting postoperative morbidity and mortality in pancreatic resections for pancreatobiliary carcinomas. *J Hepatobiliary Pancreat Sci* 2014;**21**(8):599-606.
  26. Vibert E, Boleslawski E, Cosse C, et al. Arterial Lactate Concentration at the End of an Elective Hepatectomy Is an Early Predictor of the Postoperative Course and a Potential Surrogate of Intraoperative Events. *Ann Surg* 2015;**262**(5):787-93.
  27. Poon RT, Fan ST, Lo CM, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. *Ann Surg* 2004;**240**(4):698-708; discussion 08-10.
  28. Uzunoglu FG, Reeh M, Vettorazzi E, et al. Preoperative Pancreatic Resection (PREPARE) score: a prospective multicenter-based morbidity risk score. *Ann Surg* 2014;**260**(5):857-63; discussion 63-4.
  29. Labгаа I, Demartines N, Hubner M. Biomarkers Capable to Early Predict Postoperative Complications: The Grail. *Ann Surg* 2016.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
30. Cerantola Y, Hubner M, Grass F, et al. Immunonutrition in gastrointestinal surgery. *Br J Surg* 2011;**98**(1):37-48.
31. Carli F. Physiologic considerations of Enhanced Recovery After Surgery (ERAS) programs: implications of the stress response. *Can J Anaesth* 2015;**62**(2):110-9.
32. Ljungqvist O, Nygren J, Soop M, et al. Metabolic perioperative management: novel concepts. *Curr Opin Crit Care* 2005;**11**(4):295-9.
33. de la Motte L, Kehlet H, Vogt K, et al. Preoperative methylprednisolone enhances recovery after endovascular aortic repair: a randomized, double-blind, placebo-controlled clinical trial. *Ann Surg* 2014;**260**(3):540-8; discussion 48-9.



**Table 1: Baseline characteristics of patients with and without postoperative complications.**

|                                 | Pat. with complications (n=60) | Pat. without complications (n=78) | p-value      |
|---------------------------------|--------------------------------|-----------------------------------|--------------|
| Demographics                    |                                |                                   |              |
| Median age (years)              | 64 (50-73)                     | 59 (51-69)                        | 0.306        |
| Age ≥ 70 years                  | 20 (51)                        | 19 (49)                           | 0.246        |
| Gender (male)                   | 38 (63)                        | 34 (44)                           | <b>0.021</b> |
| Median BMI (kg/m <sup>2</sup> ) | 24 (22-28)                     | 26 (22-31)                        | <b>0.038</b> |
| BMI ≥25 kg/m <sup>2</sup>       | 27 (47)                        | 46 (60)                           | 0.128        |
| Comorbidities                   |                                |                                   |              |
| ASA (I-II)                      | 36 (60)                        | 52 (67)                           | 0.419        |
| ECOG (0-1)                      | 45 (75)                        | 66 (85)                           | 0.158        |
| Cirrhosis                       | 2 (3)                          | 1 (1)                             | 0.413        |
| Heart disease                   | 10 (17)                        | 12 (16)                           | 0.864        |
| Lung disease                    | 8 (13)                         | 7 (9)                             | 0.415        |
| Diabetes                        | 8 (13)                         | 13 (17)                           | 0.589        |
| History of surgery              | 33 (55)                        | 42 (55)                           | 0.958        |
| Cancer                          | 45 (75)                        | 54 (69)                           | 0.456        |
| Surgery                         |                                |                                   |              |
| Type                            |                                |                                   |              |
| Colorectal                      | 14 (23)                        | 17 (22)                           | 0.840        |
| HPB                             | 31 (52)                        | 19 (24)                           | 0.001        |
| Upper-GI                        | 11 (18)                        | 17 (22)                           | 0.674        |
| Other                           | 4 (7)                          | 25 (32)                           | <0.001       |
| Approach                        |                                |                                   |              |
| Open                            | 50 (83)                        | 29 (37)                           |              |
| Laparoscopy                     | 10 (17)                        | 49 (63)                           |              |
| Duration                        |                                |                                   |              |
| Median (min)                    | 271 (224-340)                  | 154 (112-239)                     | <0.001       |
| ≥ 180 min                       | 46 (77)                        | 33 (42)                           | <0.001       |
| Blood Loss                      |                                |                                   |              |
| Median (mL)                     | 300 (100-575)                  | 90 (0-263)                        | 0.002        |
| ≥ 200 mL                        | 40 (67)                        | 24 (31)                           | <0.001       |
| Median mE-PASS                  | 0.77 (0.57-1.03)               | 0.49 (0.4-0.81)                   | 0.12         |

BMI: Body mass index; ASA: American Association of Anesthesiologists physical status classification system; ECOG: Eastern Cooperative Oncology Group performance status; cancer: operative indication; HPB: Hepato-Pancreatico-Biliary surgery; Upper-GI: Upper-Gastrointestinal surgery; mE-PASS: Modified Estimation of Physiologic Ability and Surgical Stress; CCI: Comprehensive complication index; LoS: Length of stay. Other surgeries included pressurized intra-abdominal aerosol chemotherapy (17), endocrine operations

1  
2 (4), complex abdominal wall operations (2), resections of retroperitoneal sarcomas (3), nephrectomy (1), and  
3  
4 interrupted limb perfusions for melanoma (2).  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 2: Logistic regression with uni- and multivariable analysis for predictors of postoperative complications.**

|                            | Overall postoperative complications |            |                  |               |            |              |
|----------------------------|-------------------------------------|------------|------------------|---------------|------------|--------------|
|                            | Univariable                         |            |                  | Multivariable |            |              |
|                            | HR                                  | 95% CI     | p-value          | HR            | 95% CI     | p-value      |
| Age > 70 years             | 1.55                                | 0.74-3.27  | 0.247            |               |            |              |
| Gender (Female)            | 0.45                                | 0.22-0.89  | <b>0.022</b>     | 1.06          | 0.38-2.96  | 0.905        |
| ASA I/II                   | 1.33                                | 0.66-2.68  | 0.42             |               |            |              |
| ECOG 0/1                   | 1.83                                | 0.79-4.28  | 0.161            |               |            |              |
| Cirrhosis                  | 2.66                                | 0.24-30    | 0.43             |               |            |              |
| Cancer                     | 1.33                                | 0.63-2.84  | 0.456            |               |            |              |
| Diabetes                   | 0.77                                | 0.3-2      | 0.59             |               |            |              |
| BMI > 25 kg/m <sup>2</sup> | 0.59                                | 0.3-1.17   | 0.129            |               |            |              |
| Approach (open)            | 8.49                                | 3.72-19.18 | <b>&lt;0.001</b> | 11.22         | 2.74-46.05 | <b>0.001</b> |
| Duration ≥ 180 min         | 4.48                                | 2.12-9.47  | <b>&lt;0.001</b> | 0.47          | 0.11-1.94  | 0.297        |
| Blood loss ≥ 200 mL        | 4.50                                | 2.19-9.25  | <b>&lt;0.001</b> | 1.68          | 0.57-4.99  | 0.350        |
| ΔAlb POD1 ≥ 10 g/L         | 6.89                                | 2.94-16.14 | <b>&lt;0.001</b> | 3.29          | 1.14-9.49  | <b>0.028</b> |

ASA: American Association of Anesthesiologists physical status classification system; ECOG: Eastern Cooperative Oncology Group performance status; BMI: Body mass index; ΔAlb POD1: The difference between serum albumin concentration on POD -1 and POD 1 (g/L).

**LEGENDS****Figure 1:**

$\Delta$ Alb on POD1 correlates with the extent of surgery.  $\Delta$ Alb on POD1 showed a significant correlation with (a) mE-PASS ( $r=0.275$ ,  $p=0.01$ ), (b) blood loss ( $r=0.391$ ,  $p<0.001$ ), and (c) duration of surgery ( $r=0.562$ ,  $p<0.001$ ).

**Figure 2:**

The postoperative decrease of Alb on POD 1 correlated with outcomes.  $\Delta$ Alb on POD1 showed a significant correlation with CCI (Comprehensive complication index) (a), and with length of stay (LoS) (b).

**Figure 3:**

Receiver operating characteristic (ROC) curve to determine the optimal cut-off of  $\Delta$ Alb on POD1 (blue line), showed an AUC of 0.78.

**Supplementary Figure 1:**

Mean perioperative concentration of serum albumin (vertical bars illustrate standard deviations).

**Supplementary Figure 2:**

$\Delta$ CRP (a),  $\Delta$ PCT (b) and  $\Delta$ LCT (c) on POD1 yielded AUC of 0.73, 0.63 and 0.64, respectively. The AUC of  $\Delta$ CRP on POD4 was 0.75 (d).

**Contributorship statement:**

IL involved in study design, data collection, analysis and interpretation, review of the literature, drafting and critical revision of the manuscript. GRJ involved in study design, data collection, analysis and interpretation, review of the literature, critical revision of the manuscript. AK involved in data collection, analysis and interpretation, review of the literature, critical revision of the manuscript. SM involved in data collection, analysis and interpretation, review of the literature, critical revision of the manuscript. MS involved in study design, analysis and interpretation, critical revision of the manuscript. ND involved in study design, analysis and interpretation, critical revision of the manuscript. MH study design, analysis and interpretation, drafting and critical revision of the manuscript.


**Competing interests:** There are no conflicts of interest relevant to the nature of this manuscript.

**Sources of funding:** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors

**Data sharing statement:** There is no additional data.


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1: The intensity of ΔAlb on POD1 Correlates with the Extent of Surgery



190x254mm (96 x 96 DPI)

Figure 2:  $\Delta$ Alb on POD1 Correlates with Complications (CCI) and Length of Stay (LoS)




254x190mm (96 x 96 DPI)

ew only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


**Figure 3:** Receiver operating characteristic (ROC) curve of  $\Delta$ Alb on POD1



190x254mm (96 x 96 DPI)



Supplementary Figure 1: Perioperative Kinetics of Serum Albumin (Alb)




190x254mm (96 x 96 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Supplementary Figure 2: Receiver operating characteristic (ROC) curves of other stress markers



190x254mm (96 x 96 DPI)

Supplementary Table 1: Correlations of the candidate biomarkers with outcomes.

|            |         | mE-PASS |                  | Minor (I-II) |              | Major (III-V) |                  | Overall complication |                  | CCI     |                  | LoS     |                  |
|------------|---------|---------|------------------|--------------|--------------|---------------|------------------|----------------------|------------------|---------|------------------|---------|------------------|
|            |         | Pearson | p-value          | Spearman     | p-value      | Spearman      | p-value          | Spearman             | p-value          | Pearson | p-value          | Pearson | p-value          |
| <b>CRP</b> | Δ Max   | 0.062   | 0.530            | 0.256        | <b>0.003</b> | 0.387         | <b>&lt;0.001</b> | 0.534                | <b>&lt;0.001</b> | 0.529   | <b>&lt;0.001</b> | 0.484   | <b>&lt;0.001</b> |
|            | Δ POD 0 | 0.052   | 0.693            | 0.070        | 0.566        | 0.049         | 0.686            | 0.098                | 0.417            | 0.231   | 0.052            | 0.381   | <b>0.001</b>     |
|            | Δ POD 1 | 0.116   | 0.256            | 0.207        | <b>0.024</b> | 0.273         | <b>0.003</b>     | 0.395                | <b>&lt;0.001</b> | 0.469   | <b>&lt;0.001</b> | 0.462   | <b>&lt;0.001</b> |
| <b>Alb</b> | Δ Max   | 0.323   | <b>0.001</b>     | 0.264        | <b>0.003</b> | 0.345         | <b>&lt;0.001</b> | 0.470                | <b>&lt;0.001</b> | 0.373   | <b>&lt;0.001</b> | 0.358   | <b>&lt;0.001</b> |
|            | Δ POD 0 | 0.479   | <b>&lt;0.001</b> | 0.298        | <b>0.006</b> | 0.194         | 0.077            | 0.420                | <b>&lt;0.001</b> | 0.302   | <b>0.005</b>     | 0.259   | <b>0.018</b>     |
|            | Δ POD 1 | 0.275   | <b>0.010</b>     | 0.228        | <b>0.016</b> | 0.372         | <b>&lt;0.001</b> | 0.485                | <b>&lt;0.001</b> | 0.383   | <b>&lt;0.001</b> | 0.468   | <b>&lt;0.001</b> |
| <b>PCT</b> | Δ Max   | -0.050  | 0.656            | 0.240        | <b>0.016</b> | 0.181         | 0.071            | 0.339                | <b>0.001</b>     | 0.140   | 0.162            | 0.204   | <b>0.040</b>     |
|            | Δ POD 0 | 0.017   | 0.906            | 0.171        | 0.204        | 0.076         | 0.570            | 0.211                | 0.112            | 0.015   | 0.909            | 0.168   | 0.206            |
|            | Δ POD 1 | -0.010  | 0.933            | 0.135        | 0.216        | 0.150         | 0.165            | 0.220                | <b>0.041</b>     | -0.034  | 0.752            | 0.103   | 0.342            |
| <b>LCT</b> | Δ Max   | 0.269   | <b>0.013</b>     | 0.301        | <b>0.003</b> | 0.196         | 0.057            | 0.426                | <b>&lt;0.001</b> | 0.317   | <b>0.002</b>     | 0.327   | <b>0.001</b>     |
|            | Δ POD 0 | 0.244   | <b>0.039</b>     | 0.297        | <b>0.007</b> | 0.178         | 0.111            | 0.412                | <b>&lt;0.001</b> | 0.299   | <b>0.007</b>     | 0.292   | <b>0.008</b>     |
|            | Δ POD 1 | 0.118   | 0.331            | 0.265        | <b>0.018</b> | 0.026         | 0.817            | 0.248                | <b>0.026</b>     | 0.193   | 0.087            | 0.104   | 0.360            |

Complications are graded according to the Clavien classification (grade I to V); mE-PASS: Modified Estimation of Physiologic Ability and Surgical Stress; CCI: Comprehensive complication index; LoS: Length of stay; CRP: C-reactive protein; Alb: Serum albumin; PCT: Procalcitonin; LCT: Lactates; Δ Max: Maximal difference between the pre- and post-operative values; Δ POD 0: Difference of concentration on POD -1 and POD 0; Δ Pod 1: Difference of concentration on POD -1 and POD 1

Supplementary Table 2: Discriminatory ability of albumin decrease on POD1

|                      | $\Delta$ Alb POD1 |               | p-value          |
|----------------------|-------------------|---------------|------------------|
|                      | <10 g/L           | $\geq$ 10 g/L |                  |
| <b>Complications</b> |                   |               |                  |
| Minor (I-II)         | 8 (15)            | 21 (36)       | <b>0.011</b>     |
| Major (III-V)        | 3 (6)             | 16 (28)       | <b>0.002</b>     |
| Overall              | 11 (20)           | 37 (64)       | <b>&lt;0.001</b> |
| CCI                  | 0                 | 20.9 (0-33.5) | <b>&lt;0.001</b> |
| <b>LoS</b>           | 4 (4-7)           | 13 (13-21)    | <b>&lt;0.001</b> |

Complications are graded according to the Clavien classification (grade I to V);  $\Delta$ Alb POD1: The difference between serum albumin concentration on POD -1 and POD 1 (g/L); mE-PASS: Modified Estimation of Physiologic Ability and Surgical Stress; CCI: Comprehensive complication index; LoS: Length of stay

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

| Section/Topic                | Item # | Recommendation   | Reported on page # |
|------------------------------|--------|--|--------------------|
| Title and abstract           | 1      | (a) Indicate the study's design with a commonly used term in the title or the abstract   | 1                  |
|                              |        | (b) Provide in the abstract an informative and balanced summary of what was done and what was found  | 2                  |
| <b>Introduction</b>          |        |  |                    |
| Background/rationale         | 2      | Explain the scientific background and rationale for the investigation being reported   | 4                  |
| Objectives                   | 3      | State specific objectives, including any prespecified hypotheses   | 4                  |
| <b>Methods</b>               |        |  |                    |
| Study design                 | 4      | Present key elements of study design early in the paper  | 5                  |
| Setting                      | 5      | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection  | 5                  |
| Participants                 | 6      | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up   | 5                  |
|                              |        | (b) For matched studies, give matching criteria and number of exposed and unexposed  | Not applicable     |
| Variables                    | 7      | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable   | 5-6                |
| Data sources/<br>measurement | 8*     | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 5-6                |
| Bias                         | 9      | Describe any efforts to address potential sources of bias  | 5-6                |
| Study size                   | 10     | Explain how the study size was arrived at  | 5                  |
| Quantitative variables       | 11     | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why   | 5-6                |
| Statistical methods          | 12     | (a) Describe all statistical methods, including those used to control for confounding  | 6                  |
|                              |        | (b) Describe any methods used to examine subgroups and interactions  | 6                  |
|                              |        | (c) Explain how missing data were addressed  | 6                  |
|                              |        | (d) If applicable, explain how loss to follow-up was addressed   | Not applicable     |
|                              |        | (e) Describe any sensitivity analyses  | 6                  |

|                          |     |  |                |
|--------------------------|-----|--|----------------|
| <b>Results</b>           |     |  |                |
| Participants             | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed            | 7              |
|                          |     | (b) Give reasons for non-participation at each stage   | 7              |
|                          |     | (c) Consider use of a flow diagram   | Not applicable |
| Descriptive data         | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders   | 7              |
|                          |     | (b) Indicate number of participants with missing data for each variable of interest  | 16             |
|                          |     | (c) Summarise follow-up time (eg, average and total amount)  | 8              |
| Outcome data             | 15* | Report numbers of outcome events or summary measures over time   | 7-8            |
| Main results             | 16  | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 8              |
|                          |     | (b) Report category boundaries when continuous variables were categorized  | 6              |
|                          |     | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period   | Not applicable |
| Other analyses           | 17  | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses   | 8              |
| <b>Discussion</b>        |     |  |                |
| Key results              | 18  | Summarise key results with reference to study objectives   | 9              |
| <b>Limitations</b>       |     |  |                |
| Interpretation           | 20  | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence                                   | 10             |
| Generalisability         | 21  | Discuss the generalisability (external validity) of the study results  | 11             |
| <b>Other information</b> |     |  |                |
| Funding                  | 22  | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based  | 20             |

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

# BMJ Open

## Assessing Postoperative Decrease of Serum Albumin as an Early Predictor of Complications After Major Abdominal Surgery: A Prospective Cohort Study

|                                 |  |
|---------------------------------|--|
| Journal:                        | <i>BMJ Open</i>  |
| Manuscript ID                   | bmjopen-2016-013966.R1   |
| Article Type:                   | Research   |
| Date Submitted by the Author:   | 23-Nov-2016  |
| Complete List of Authors:       | Labgaa, Ismail; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Joliat, Gaëtan-Romain ; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Kefleyesus, Amanuel; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Mantziari, Styliani; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Schäfer, Markus; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Demartines, Nicolas; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>HUBNER, Martin; University Hospital of Lausanne (CHUV), Department of Visceral Surgery |
| <b>Primary Subject Heading</b>: | Surgery  |
| Secondary Subject Heading:      | Surgery  |
| Keywords:                       | Biomarker, albumin, major surgery, postoperative complications, stress response  |
|                                 |  |

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

*Research Article*

**Assessing Postoperative Decrease of Serum Albumin as an Early Predictor of Complications After Major Abdominal Surgery: A Prospective Cohort Study**

Ismail Labgaa<sup>1\*</sup>, Gaëtan-Romain Joliat<sup>1\*</sup>, Amanuel Kefleyesus<sup>1</sup>, Styliani Mantziari<sup>1</sup>, Markus Schäfer<sup>1</sup>, Nicolas Demartines<sup>1</sup>, Martin Hübner<sup>1</sup>

<sup>1</sup> Department of Visceral Surgery, Lausanne University Hospital CHUV, Switzerland

\* Equal contribution

**Corresponding author:**

Nicolas Demartines, MD, FACS, FRCS

Professor and Chairman

Department of visceral surgery

University Hospital CHUV

1011 Lausanne, Switzerland

Phone: +41 21 314 24 00 / Fax: +41 21 314 24 11

E-mail: [demartines@chuv.ch](mailto:demartines@chuv.ch)

The present study was presented at the 103<sup>rd</sup> Congress of Swiss Surgery (June 2016, Lugano, Switzerland) and at the Clinical Congress of the American College of Surgeons (October 2016, Washington, DC, USA).

**Key words:** Biomarker; albumin; major surgery; postoperative complications; stress response

**Word count:** 3106



## ABSTRACT

**Objective:** To test postoperative serum albumin drop ( $\Delta$ Alb) as a marker of surgical stress response and early predictor of clinical outcomes.

**Design:** Prospective cohort study (NCT02356484). Albumin was prospectively measured in 138 patients undergoing major abdominal surgery. Blood samples were collected before surgery and on postoperative days 0, 1, 2, and 3.  $\Delta$ Alb was compared to the *Modified Estimation of Physiologic Ability and Surgical Stress* (mE-PASS) score and correlated to the performances of C-reactive protein (CRP), procalcitonin (PCT), and lactate (LCT). Postoperative outcomes were postoperative complications according to both Clavien classification and Comprehensive Complication Index (CCI), and length of hospital stay (LoS).

**Setting:** Department of abdominal surgery in a European tertiary center.

**Participants:** Adult patients undergoing elective major abdominal surgery, with anticipated duration  $\geq 2$ h. Patients on immunosuppressive or antibiotic treatments before surgery were excluded.

**Results:** The level of serum albumin rapidly dropped after surgery.  $\Delta$ Alb correlated to the mE-PASS score ( $r=0.275$ ,  $p=0.01$ ) and to CRP increase ( $r=0.536$ ,  $p<0.001$ ).  $\Delta$ Alb also correlated to overall complications ( $r=0.485$ ,  $p<0.001$ ), CCI ( $r=0.383$ ,  $p<0.001$ ) and LoS ( $r=0.468$ ,  $p<0.001$ ). A  $\Delta$ Alb  $\geq 10$  g/L yielded a sensitivity of 77.1% and a specificity of 67.2% (AUC: 78.3%) to predict complications. Patients with  $\Delta$ Alb  $\geq 10$ g/l on POD 1 showed a 3 fold increased risk of overall postoperative complications.

**Conclusion:**  $\Delta$ Alb correlated to the extent of surgery and to other biological stress markers.  $\Delta$ Alb  $\geq 10$  g/L on POD 1 appears to be a promising early predictor of postoperative complications.

## STRENGTHS AND LIMITATIONS OF THE STUDY

- The present study has a prospective design and offers a head-to-head comparison with biomarkers currently used in clinical practice (C-Reactive Protein and Procalcitonin).
- Albumin drop was thoroughly assessed by analyzing its correlation with a comprehensive panel of surrogate markers for surgical trauma and validated scores for outcomes.
- The predictive value of combined biomarkers was not assessed in the present study.
- This study involved a single center and included a training cohort, without validation cohort.

## INTRODUCTION

Abdominal surgery is among the most frequently performed elective surgery<sup>1</sup>. Although surgical and perioperative improvements have reduced postoperative mortality over the last decades, postoperative morbidity has remained high<sup>2</sup>. In addition to being troublesome experiences for patients, postoperative complications cause a substantial financial burden, while important efforts are currently pursued to reduce health care expenditures<sup>2</sup>.

The magnitude of metabolic stress response recapitulates the extent of surgery<sup>3,4</sup> and presumably contributes to the risk of developing postoperative complications<sup>5,6</sup>. Early identification of patients at risk may improve outcomes, since measures to attenuate the surgical stress response and to reduce morbidity exist<sup>7</sup>.

Although C-reactive protein (CRP) and procalcitonin (PCT) have been proposed as predictors for adverse outcomes in colorectal surgery, they both display the critical limitation of slow kinetics<sup>8,9</sup>. Conversely, serum albumin (Alb) is a maintenance protein that is rapidly downregulated by inflammatory signals<sup>4,10</sup>. Preliminary data suggested that Alb level rapidly dropped after surgery and correlated to outcomes in esophageal<sup>11</sup>, oral cancer<sup>12</sup>, abdominal<sup>4</sup>, pancreatic<sup>13</sup>, liver resection<sup>14</sup>/transplant<sup>15</sup> and cardiac<sup>16</sup> surgeries. However, prospective validation is missing and Alb is not used to assess surgical stress or to predict outcomes.

This study aimed to test the hypotheses that early postoperative albumin drop (I) reflects the magnitude of surgical trauma, (II) correlates to established markers of metabolic stress, and (III) predicts postoperative complications.

## METHODS

### Study design and patient groups

This prospective study was conducted at the Department for Visceral Surgery at the University Hospital of Lausanne Switzerland (CHUV) between February and December 2015 (NCT02356484). The study was approved by the Institutional Review Board (N°367/15) and all patients provided written consent prior to surgery. Inclusion criteria were age >18 years, and elective major abdominal surgery - defined as an operative procedure with anticipated duration  $\geq 2$ h<sup>17</sup>. Perioperative care closely adhered to recently published enhanced recovery guidelines (<http://erassociety.org.loopiadns.com/guidelines/list-of-guidelines>). Standardized fluid administration was followed by advanced hemodynamic monitoring to avoid intraoperative fluid overload. According to the clinical care pathway, intravenous fluid was typically discontinued the morning after surgery.

Demographics, comorbidities, surgical details and clinical outcomes were prospectively collected and anonymized in a computerized protected database. A two-sample t-test was used to calculate sample size, with size effect of 0.8, power of 0.99 and significance level of 0.05. This determined a required number of 50 patients per group (i.e. with complication vs. without complication). Anticipating a complication rate of 40%, the final sample size for this study was n=125 patients. In order to adjust for 10% drop-out or missing data, final sample size resulted in n=138.

### Extent of surgery

The amplitude of surgical stress was measured by the *Modified Estimation of Physiologic Ability and Surgical Stress* (mE-PASS). Briefly, mE-PASS score encompasses 7 items (6 preoperative variables and the surgical procedure). It predicts the in-hospital mortality and the 30-day mortality rates, respectively<sup>18</sup>. Type of surgery, operative time, and surgical approach (open vs. laparoscopic) were recorded. Conversions from laparoscopy to laparotomy were counted as

1  
2 laparoscopic cases. Anesthesiologists and surgeons jointly estimated blood loss by measuring the  
3  
4 volume of aspirated fluid and soaked gauzes.  
5  
6  
7

### 8 9 **Biological markers**

10  
11 Serum levels of albumin, CRP, PCT and lactate (LCT) were perioperatively measured in a  
12  
13 fasting state, following standardized institutional guidelines. Blood samples were drawn the day  
14  
15 before surgery, the day of surgery (4-6 hours after the end of the operation) and on the first, second  
16  
17 and third postoperative day. As baseline values tend to show large variations especially for  
18  
19 albumin<sup>4 10</sup>, we considered that a dynamic value (difference between two time-points) might be  
20  
21 more informative than a snapshot value. Several values based on pre- and post-operative  
22  
23 concentrations, were thus calculated for each marker (i.e.,  $\Delta$  Max: Maximal difference between the  
24  
25 pre- and post-operative values;  $\Delta$  POD 0: Difference of concentration on POD -1 and POD 0;  $\Delta$   
26  
27 POD 1: Difference of concentration on POD -1 and POD 1).  
28  
29  
30  
31  
32

### 33 34 **Outcome measures**

35  
36 Complications were graded with the Clavien classification within 30 postoperative days,  
37  
38 accounting grade I/II events as minor complications and grade III-V as major complications<sup>19</sup>.  
39  
40 Every complication was documented. Global morbidity for each patient was quantified by the  
41  
42 Comprehensive Complication Index (CCI) on a scale from 0 to 100<sup>20</sup>. Length of stay (LoS) was  
43  
44 considered as the duration from the day of surgery until discharge.  
45  
46  
47  
48

### 49 50 **Statistical analysis**

51  
52 Continuous variables were presented as mean with standard deviation (SD) or median value  
53  
54 with interquartile range (IQR) depending on the normality of the distribution and compared using  
55  
56 Student's *t* test and Mann-Whitney U test, whereas categorical variables were given as frequencies  
57  
58 with percentages and compared with chi-square test. For statistical analyses, the following  
59  
60

1  
2 parameters were dichotomized: age ( $\geq 70$  years), body-mass index ( $\geq 25$  kg/m<sup>2</sup>), operative time  
3  
4 ( $\geq 180$  minutes), and blood loss ( $\geq 200$  ml). Spearman's and Pearson's tests were used to measure  
5  
6 correlations of categorical ( $\rho$ ) and continuous ( $r$ ) variables, respectively. Receiver operating  
7  
8 characteristic (ROC) curves were applied to obtain the area under the curve (AUC), and to  
9  
10 determine ideal cut-offs. Logistic regression was applied to identify independent predictors;  
11  
12 variables with significance  $< 0.1$  in univariable analyses were further included in multivariable  
13  
14 analyses. A p value  $< 0.05$  was considered to be statistically significant in all tests. Data analyses  
15  
16 were generated using SPSS v20 statistical software (Chicago, IL).  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

### Patients Characteristics, Details of Surgery, and Outcomes

During the study period, 155 consecutive patients undergoing major abdominal surgery were potentially eligible for inclusion, but 17 of them refused to participate. As a result, 138 patients were included in the study and had a complete follow-up. Demographics and surgical details are displayed in **Table 1**. Median mE-PASS score was 0.66 (IQR 0.45-0.96).

Overall, 60/138 patients (43%) experienced at least one complication, and one patient died after total gastrectomy and splenopancreatectomy due to cardiorespiratory arrest. Minor and major complications were observed in 35 and 25 patients, respectively. Patients showed a mean CCI of 13.2 (SD 18.5), and were discharged after a median LoS of 8 days (IQR 5-15 days).

### Perioperative Profile of Biomarkers

The perioperative profile of albumin showed a rapid drop induced by surgery, followed by a plateau phase between POD 0 and POD 3 (**Supplementary Figure 1**). Lactate levels peaked in the first 4-6h after surgery and were back to baseline on POD1. Conversely, CRP and PCT showed slow kinetics reaching maximal values on POD 4 and 3, respectively. The mean maximal decrease of albumin was 11.3 g/L ( $\pm 5.6$ ), which was similar to albumin drop on POD 1: 10.1 g/L (SD: 5.8). Further analyses were hence focused on  $\Delta$ Alb on POD1.

### Correlation of $\Delta$ Alb to surgical stress, biomarkers, and outcomes

$\Delta$ Alb on POD1 correlated to surgical stress (mE-PASS) ( $r=0.275$ ,  $p=0.01$ ) and to surrogates such as duration of surgery ( $r=0.562$ ,  $p<0.001$ ), blood loss ( $r=0.391$ ,  $p<0.001$ ), and surgical approach ( $\rho=0.55$ ,  $p<0.001$ ) (**Figure 1**).

$\Delta$ Alb on POD1 also correlated to maximal increases of CRP ( $r=0.54$ ,  $p<0.001$ ), PCT ( $r=0.43$ ,  $p<0.001$ ), and LCT ( $r=0.25$ ,  $p=0.02$ ). Furthermore, a positive and significant correlation was highlighted between  $\Delta$ Alb on POD1 and  $\Delta$ CRP on POD4 ( $\rho=0.234$ ,  $p=0.044$ ).  $\Delta$ Alb on POD1 was

1 significantly associated with adverse outcomes, showing significant correlations with CCI  
2  
3  
4 ( $\rho=0.383$ ,  $p<0.001$ ) and LoS ( $\rho=0.468$ ,  $p<0.001$ ) (**Figure 2**).

5  
6 The correlations of CRP, PCT, and LCT with surgical stress and outcomes were also tested and are  
7  
8 detailed in **Supplementary Table 1**.

### 13 **Predictive Value of Albumin Decrease**

14  
15 A ROC curve was used to determine the optimal cut-off of  $\Delta\text{Alb}$  on POD1, settled at 10  
16  
17 g/L. The area under the curve (AUC) measured 78.3% (95% CI: 70-87%), giving a sensitivity of  
18  
19 77.1%, a specificity of 67.2%, a positive predictive value of 64.8%, and a negative predictive value  
20  
21 of 79.6%, for overall complications (**Figure 3**). The respective ROC curves for POD1 values of  
22  
23  $\Delta\text{CRP}$ ,  $\Delta\text{PCT}$ , and  $\Delta\text{LCT}$  are provided in **Supplementary Figure 2**.

24  
25 It was subsequently investigated whether this cut-off was able to discriminate and stratify patients'  
26  
27 risk. Patients with an intense drop of Alb on POD 1 ( $\Delta\text{Alb POD1} \geq 10$  g/L) showed a higher mE-  
28  
29 PASS (0.73 vs. 0.49,  $p=0.029$ ) with higher rates of minor (36% vs. 15%,  $p=0.011$ ), major (28% vs.  
30  
31 6%,  $p=0.002$ ), and overall complications (64% vs. 20%,  $p<0.001$ ). This resulted in a significantly  
32  
33 higher CCI (20.9 vs. 0,  $p<0.001$ ) and in a significantly longer LoS (13 vs. 4 days,  $p<0.001$ )  
34  
35 (**Supplementary Table 2**).

36  
37  
38  
39  
40 Logistic regression with multivariable analysis identified open surgery (OR: 11.22; 95% CI: 2.74-  
41  
42 46.05;  $p=0.001$ ) and  $\Delta\text{Alb POD1} \geq 10$  g/L (OR: 3.29; 95% CI: 1.14-9.49;  $p=0.028$ ) to be  
43  
44 independently associated with overall complications (**Table 2**).



## DISCUSSION

Surgery induced a rapid decrease of serum albumin in patients undergoing elective major abdominal procedures; and it remained stable for several postoperative days. Although correlation coefficients were modest, the decrease in serum albumin significantly correlated with (I) the extent of surgery (mE-PASS, blood loss, duration of surgery, and surgical approach), (II) the maximal amplitude of other stress markers, such as CRP, PCT and LCT and (III) was consistently associated with adverse outcomes (according to both Clavien classification, CCI, and LoS). A serum albumin decrease  $\geq 10$  g/L on POD 1 was independently associated with a 3-fold increased risk for postoperative complication.

The present study tested a panel of 4 biomarkers of which 2 are routinely used and served as benchmarks (CRP and PCT) and 2 are less established markers and deserved prospective investigations (Alb and LCT). The mE-PASS accurately recapitulates surgical stress, and was validated and used in abdominal surgery<sup>18 21-24</sup>. To our knowledge, there is no other validated and available score. One study endpoint was the CCI, which is a score summing each complication graded according to the Clavien classification. As a result, CCI avoids omitting minor complications, and is therefore more accurate than the Clavien classification alone<sup>20</sup>. Serum albumin showed the more consistent correlation with stress response and clinical outcomes. Alb and LCT both display some of the features for ideal markers: easy to measure and to interpret, readily available, can be repeated for monitoring and non-expensive. While Alb rapidly dropped after surgery and subsequently stabilized until POD 3, lactate showed a prompt increase followed by a fast return to baseline value, already on POD 1. It can be assumed that the timing of blood collection may have a more important impact on LCT than on Alb. As a consequence, Alb is more robust and easier to use in clinical setting. Importantly, the selected markers were repeatedly measured, which allowed to capture their perioperative profiles and to further calculate differences of concentrations between various time-points. The latter was revealed to be pivotal and more informative than a single value.

1  
2 The mechanisms of early postoperative albumin decrease combine altered metabolism,  
3  
4 blood loss/dilution and most importantly redistribution into the third space, due to capillary  
5  
6 leakage. The latter accounts for >75% of albumin decrease in the early postoperative phase and  
7  
8 appears to be related to the magnitude of systemic inflammatory response<sup>10 25 26</sup>. Therefore,  
9  
10 albumin decrease is certainly influenced by perioperative fluid management (liberal vs. restrictive)  
11  
12 but it mainly reflects the extent of postsurgical stress response.  
13  
14

15  
16 In multivariable analysis (table 2), 2 factors were independently associated with  
17  
18 complications: approach and  $\Delta\text{Alb POD1} \geq 10$  g/L. The overlap of certain parameters of surgical  
19  
20 stress may, in part, explain why they were not identified as independent predictor of complication.  
21  
22 It may also suggest that serum albumin recapitulates these different parameters.  
23

24  
25 Some limitations need to be addressed. The present analyses were focused on 4 markers  
26  
27 that are readily available and easy to evaluate in clinical setting. This non-inclusive panel of  
28  
29 markers could be perceived as a methodological shortcoming. Notwithstanding, integrating more  
30  
31 complex and costly markers would unlikely to be more informative given their poor  
32  
33 reproducibility, cost and assay measurement complexity. Likewise, this study did not assess the  
34  
35 predictive value of albumin drop combined with other biomarker and/or clinical variables.  
36  
37 Although such a classifier may presumably improve sensitivity and specificity, it will also be more  
38  
39 complex which could ultimately preclude its implementation in clinical practice. Blood collection  
40  
41 on POD 0 occurred 4-6 hours after the end of surgery. This delay might be long enough to alter the  
42  
43 discriminatory ability of certain markers, particularly lactate<sup>27</sup>.  
44  
45

46  
47 Available data on the predictive role of postoperative Alb are scarce; and most of these  
48  
49 reports were retrospective studies<sup>11-13 16 28</sup>. Of note, each of the studies investigated only a single  
50  
51 postoperative value of serum albumin. This represents a critical drawback as it cannot be  
52  
53 discerned whether the low postoperative concentration of serum albumin resulted from intense  
54  
55 surgical stress or from low preoperative level, which is an acknowledged predictor of increased  
56  
57 postoperative complication<sup>29 30</sup>. A prospective pilot study in abdominal surgery – conducted  
58  
59  
60

1 recently in our institution- showed consistent findings, with an increased risk of complication  
2 related to the amplitude of serum albumin postoperative drop <sup>4</sup>. Of note, the cohorts from this  
3 previous study (70 patients) and from the present one (138 patients) were strictly distinct.  
4  
5  
6  
7  
8  
9 Postoperative lactate has been more thoroughly explored in liver surgery, with few reports in other  
10 surgical fields. In a recent landmark study, Vibert et al. demonstrated that a postoperative cut-off  
11 of arterial lactate > 3mmol/L at the end of surgery was an independent predictor of complications  
12 after elective hepatectomies <sup>27</sup>. Their conclusion correlates with the present findings since  $\Delta$ LCT  
13 POD0 was correlated with mE-PASS (p=0.039), overall complication (p<0.001), CCI (p=0.007)  
14 and LoS (p=0.008) (**Figure 2**). Although both CRP and PCT are routinely used markers in clinical  
15 practice, they are typically contributive on POD 4 only. The present study design allowed to  
16 confirm the ultimate advantage of Alb to be up-regulated within the early postoperative phase,  
17 illustrated by the correlation between  $\Delta$ Alb on POD1 and  $\Delta$ CRP on POD4 ( $\rho=0.234$ ,  $p=0.044$ ),  
18 highlighted in this study. In fact,  $\Delta$ Alb on POD1 was more sensitive than  $\Delta$ CRP on POD4,  
19 illustrated by AUC of 0.78 and 0.75, respectively (Figure 3 and Supplementary 3D).  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 How the monitoring of Alb in surgical patients can lead to better outcomes is key question.  
34  
35 Measures to preoperatively attenuate the stress response to surgery have been extensively  
36 explored. Interestingly, successful attempts were reported with immunonutrition <sup>31</sup>, enhanced  
37 recovery programs (ERAS) <sup>32,33</sup>, or high-dose glucocorticoids <sup>34</sup>. Whether these options would be  
38 able to restrain the stress response, once triggered, in the early postoperative phase remains to be  
39 investigated. In this setting, albumin drop may facilitate to test whether these measures may also  
40 be beneficial in the early postoperative phase, by permitting to design clinical trials enriched for  
41 patients at higher risk.  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 In summary, early postoperative decrease of serum albumin correlated with the (I)  
52 extent of surgery, (II) its metabolic response, and with (III) adverse outcomes such as  
53 complications and length of hospital stay. A decreased concentration of serum albumin  $\geq 10$ g/l on  
54 POD 1 was associated with a 3-fold increased risk of overall postoperative complications; albumin  
55  
56  
57  
58  
59  
60

1  
2 decrease occurs rapidly after surgery, remains stable for several days. As it is easy to measure, it  
3  
4 could be used to identify patients at risk.  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**REFERENCES**

1. Noordzij PG, Poldermans D, Schouten O, et al. Postoperative mortality in The Netherlands: a population-based analysis of surgery-specific risk in adults. *Anesthesiology* 2010;**112**(5):1105-15.
2. Vonlanthen R, Slankamenac K, Breitenstein S, et al. The impact of complications on costs of major surgical procedures: a cost analysis of 1200 patients. *Ann Surg* 2011;**254**(6):907-13.
3. Thorell A, Nygren J, Ljungqvist O. Insulin resistance: a marker of surgical stress. *Curr Opin Clin Nutr Metab Care* 1999;**2**(1):69-78.
4. Mantziari S, Hubner M, Coti-Bertrand P, et al. A Novel Approach to Major Surgery: Tracking Its Pathophysiologic Footprints. *World J Surg* 2015;**39**(11):2641-51.
5. Kohl BA, Deutschman CS. The inflammatory response to surgery and trauma. *Curr Opin Crit Care* 2006;**12**(4):325-32.
6. Amar D, Zhang H, Park B, et al. Inflammation and outcome after general thoracic surgery. *Eur J Cardiothorac Surg* 2007;**32**(3):431-4.
7. Hall R. Identification of inflammatory mediators and their modulation by strategies for the management of the systemic inflammatory response during cardiac surgery. *J Cardiothorac Vasc Anesth* 2013;**27**(5):983-1033.
8. Facy O, Paquette B, Orry D, et al. Diagnostic Accuracy of Inflammatory Markers As Early Predictors of Infection After Elective Colorectal Surgery: Results From the IMACORS Study. *Ann Surg* 2016;**263**(5):961-6.
9. Giaccaglia V, Salvi PF, Antonelli MS, et al. Procalcitonin Reveals Early Dehiscence in Colorectal Surgery: The PREDICS Study. *Ann Surg* 2016;**263**(5):967-72.
10. Hubner M, Mantziari S, Demartines N, et al. Postoperative Albumin Drop Is a Marker for Surgical Stress and a Predictor for Clinical Outcome: A Pilot Study. *Gastroenterol Res Pract* 2016;**2016**:8743187.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
11. Ryan AM, Hearty A, Prichard RS, et al. Association of hypoalbuminemia on the first postoperative day and complications following esophagectomy. *J Gastrointest Surg* 2007;**11**(10):1355-60.
12. Lee JI, Kwon M, Roh JL, et al. Postoperative hypoalbuminemia as a risk factor for surgical site infection after oral cancer surgery. *Oral Dis* 2015;**21**(2):178-84.
13. Fujiwara Y, Shiba H, Shirai Y, et al. Perioperative serum albumin correlates with postoperative pancreatic fistula after pancreaticoduodenectomy. *Anticancer Res* 2015;**35**(1):499-503.
14. Labgaa I, Joliat GR, Demartines N, et al. Serum albumin is an early predictor of complications after liver surgery. *Dig Liver Dis* 2016;**48**(5):559-61.
15. Sang BH, Bang JY, Song JG, et al. Hypoalbuminemia Within Two Postoperative Days Is an Independent Risk Factor for Acute Kidney Injury Following Living Donor Liver Transplantation: A Propensity Score Analysis of 998 Consecutive Patients. *Crit Care Med* 2015;**43**(12):2552-61.
16. Lee EH, Chin JH, Choi DK, et al. Postoperative hypoalbuminemia is associated with outcome in patients undergoing off-pump coronary artery bypass graft surgery. *J Cardiothorac Vasc Anesth* 2011;**25**(3):462-8.
17. Hubner M, Cerantola Y, Grass F, et al. Preoperative immunonutrition in patients at nutritional risk: results of a double-blinded randomized clinical trial. *Eur J Clin Nutr* 2012;**66**(7):850-5.
18. Haga Y, Ikejiri K, Wada Y, et al. A multicenter prospective study of surgical audit systems. *Ann Surg* 2011;**253**(1):194-201.
19. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;**240**(2):205-13.
20. Slankamenac K, Graf R, Barkun J, et al. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. *Ann Surg* 2013;**258**(1):1-7.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
21. Haga Y, Ikejiri K, Takeuchi H, et al. Value of general surgical risk models for predicting postoperative liver failure and mortality following liver surgery. *J Surg Oncol* 2012;**106**(7):898-904.
22. Haga Y, Wada Y, Takeuchi H, et al. Evaluation of modified Estimation of Physiologic Ability and Surgical Stress in gastric carcinoma surgery. *Gastric Cancer* 2012;**15**(1):7-14.
23. Haga Y, Wada Y, Takeuchi H, et al. Evaluation of modified estimation of physiologic ability and surgical stress in patients undergoing surgery for choledochocystolithiasis. *World J Surg* 2014;**38**(5):1177-83.
24. Haga Y, Wada Y, Saitoh T, et al. Value of general surgical risk models for predicting postoperative morbidity and mortality in pancreatic resections for pancreatobiliary carcinomas. *J Hepatobiliary Pancreat Sci* 2014;**21**(8):599-606.
25. Smeets HJ, Kievit J, Dulfer FT, et al. Analysis of post-operative hypalbuminaemia: a clinical study. *Int Surg* 1994;**79**(2):152-7.
26. Fleck A, Raines G, Hawker F, et al. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. *Lancet* 1985;**1**(8432):781-4.
27. Vibert E, Boleslawski E, Cosse C, et al. Arterial Lactate Concentration at the End of an Elective Hepatectomy Is an Early Predictor of the Postoperative Course and a Potential Surrogate of Intraoperative Events. *Ann Surg* 2015;**262**(5):787-93.
28. Sang BH, Bang JY, Song JG, et al. Hypoalbuminemia Within Two Postoperative Days Is an Independent Risk Factor for Acute Kidney Injury Following Living Donor Liver Transplantation: A Propensity Score Analysis of 998 Consecutive Patients. *Crit Care Med* 2015.
29. Poon RT, Fan ST, Lo CM, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. *Ann Surg* 2004;**240**(4):698-708; discussion 08-10.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
30. Uzunoglu FG, Reeh M, Vettorazzi E, et al. Preoperative Pancreatic Resection (PREPARE) score: a prospective multicenter-based morbidity risk score. *Ann Surg* 2014;**260**(5):857-63; discussion 63-4.
31. Cerantola Y, Hubner M, Grass F, et al. Immunonutrition in gastrointestinal surgery. *Br J Surg* 2011;**98**(1):37-48.
32. Carli F. Physiologic considerations of Enhanced Recovery After Surgery (ERAS) programs: implications of the stress response. *Can J Anaesth* 2015;**62**(2):110-9.
33. Ljungqvist O, Nygren J, Soop M, et al. Metabolic perioperative management: novel concepts. *Curr Opin Crit Care* 2005;**11**(4):295-9.
34. de la Motte L, Kehlet H, Vogt K, et al. Preoperative methylprednisolone enhances recovery after endovascular aortic repair: a randomized, double-blind, placebo-controlled clinical trial. *Ann Surg* 2014;**260**(3):540-8; discussion 48-9.



**Table 1: Baseline characteristics of patients with and without postoperative complications.**

|               |                                  | Pat. with<br>complications (n=60)<br>n (%) | Pat. without<br>complications (n=78)<br>n (%) | p-value      |
|---------------|----------------------------------|--|---|--------------|
| Demographics  |                                  |  |   |              |
|               | Median age (years)*              | 64 (50-73)                                 | 59 (51-69)                                    | 0.306        |
|               | Age ≥ 70 years                   | 20 (51)                                    | 19 (49)                                       | 0.246        |
|               | Gender (male)                    | 38 (63)                                    | 34 (44)                                       | <b>0.021</b> |
|               | Median BMI (kg/m <sup>2</sup> )* | 24 (22-28)                                 | 26 (22-31)                                    | <b>0.038</b> |
|               | BMI ≥25 kg/m <sup>2</sup>        | 27 (47)                                    | 46 (60)                                       | 0.128        |
| Comorbidities |                                  |  |   |              |
|               | ASA (I-II)                       | 36 (60)                                    | 52 (67)                                       | 0.419        |
|               | ECOG (0-1)                       | 45 (75)                                    | 66 (85)                                       | 0.158        |
|               | Cirrhosis                        | 2 (3)                                      | 1 (1)   | 0.413        |
|               | Heart disease                    | 10 (17)                                    | 12 (16)                                       | 0.864        |
|               | Lung disease                     | 8 (13)                                     | 7 (9)   | 0.415        |
|               | Diabetes                         | 8 (13)                                     | 13 (17)                                       | 0.589        |
|               | History of surgery               | 33 (55)                                    | 42 (55)                                       | 0.958        |
|               | Cancer                           | 45 (75)                                    | 54 (69)                                       | 0.456        |
| Surgery       |                                  |  |   |              |
|               | Type                             |  |   |              |
|               | Colorectal                       | 14 (23)                                    | 17 (22)                                       | 0.840        |
|               | HPB                              | 31 (52)                                    | 19 (24)                                       | 0.001        |
|               | Upper-GI                         | 11 (18)                                    | 17 (22)                                       | 0.674        |
|               | Other                            | 4 (7)                                      | 25 (32)                                       | <0.001       |
|               | Approach                         |  |   | <0.001       |
|               | Open                             | 50 (83)                                    | 29 (37)                                       |              |
|               | Laparoscopy                      | 10 (17)                                    | 49 (63)                                       |              |
|               | Duration Median (min)*           | 271 (224-340)                              | 154 (112-239)                                 | <0.001       |
|               | ≥ 180 min                        | 46 (77)                                    | 33 (42)                                       | <0.001       |
|               | Blood Loss Median (mL)*          | 300 (100-575)                              | 90 (0-263)                                    | 0.002        |
|               | ≥ 200 mL                         | 40 (67)                                    | 24 (31)                                       | <0.001       |
|               | Median mE-PASS*                  | 0.77 (0.57-1.03)                           | 0.49 (0.4-0.81)                               | 0.12         |

BMI: Body mass index; ASA: American Association of Anesthesiologists physical status classification system; ECOG: Eastern Cooperative Oncology Group performance status; cancer: operative indication; HPB: Hepato-Pancreatico-Biliary surgery; Upper-GI: Upper-Gastrointestinal surgery; mE-PASS: Modified Estimation of Physiologic Ability and Surgical Stress; CCI: Comprehensive complication index; LoS: Length of stay. Other surgeries included pressurized intra-abdominal aerosol chemotherapy (17), endocrine operations (4), complex abdominal wall operations (2), resections of retroperitoneal sarcomas (3), nephrectomy (1), and interrupted limb perfusions for melanoma (2). \* Median values (IQR)

**Table 2: Logistic regression with uni- and multivariable analysis for predictors of postoperative complications.**

|                                 | Overall postoperative complications |            |                  |               |            |              |
|---------------------------------|-------------------------------------|------------|------------------|---------------|------------|--------------|
|                                 | Univariable                         |            |                  | Multivariable |            |              |
|                                 | OR                                  | 95% CI     | p-value          | OR            | 95% CI     | p-value      |
| Age $\geq$ 70 years             | 1.55                                | 0.74-3.27  | 0.247            |               |            |              |
| Gender (Female)                 | 0.45                                | 0.22-0.89  | <b>0.022</b>     | 1.06          | 0.38-2.96  | 0.905        |
| ASA I/II                        | 1.33                                | 0.66-2.68  | 0.42             |               |            |              |
| ECOG 0/1                        | 1.83                                | 0.79-4.28  | 0.161            |               |            |              |
| Cirrhosis                       | 2.66                                | 0.24-30    | 0.43             |               |            |              |
| Cancer                          | 1.33                                | 0.63-2.84  | 0.456            |               |            |              |
| Diabetes                        | 0.77                                | 0.3-2      | 0.59             |               |            |              |
| BMI $\geq$ 25 kg/m <sup>2</sup> | 0.59                                | 0.3-1.17   | 0.129            |               |            |              |
| Approach (open)                 | 8.49                                | 3.72-19.18 | <b>&lt;0.001</b> | 11.22         | 2.74-46.05 | <b>0.001</b> |
| Duration $\geq$ 180 min         | 4.48                                | 2.12-9.47  | <b>&lt;0.001</b> | 0.47          | 0.11-1.94  | 0.297        |
| Blood loss $\geq$ 200 mL        | 4.50                                | 2.19-9.25  | <b>&lt;0.001</b> | 1.68          | 0.57-4.99  | 0.350        |
| $\Delta$ Alb POD1 $\geq$ 10 g/L | 6.89                                | 2.94-16.14 | <b>&lt;0.001</b> | 3.29          | 1.14-9.49  | <b>0.028</b> |

ASA: American Association of Anesthesiologists physical status classification system; ECOG: Eastern Cooperative Oncology Group performance status; BMI: Body mass index;  $\Delta$ Alb POD1: The difference between serum albumin concentration on POD -1 and POD 1 (g/L). OR: odds ratio

## LEGENDS

### Figure 1:

$\Delta$ Alb on POD1 correlates with the extent of surgery.  $\Delta$ Alb on POD1 showed a significant correlation with (a) mE-PASS ( $r=0.275$ ,  $p=0.01$ ), (b) blood loss ( $r=0.391$ ,  $p<0.001$ ), and (c) duration of surgery ( $r=0.562$ ,  $p<0.001$ ).

### Figure 2:

The postoperative decrease of Alb on POD 1 correlated with outcomes.  $\Delta$ Alb on POD1 showed a significant correlation with CCI (Comprehensive complication index) (a), and with length of stay (LoS) (b).

### Figure 3:

Receiver operating characteristic (ROC) curve to determine the optimal cut-off of  $\Delta$ Alb on POD1 (blue line), showed an AUC of 0.78.

### Supplementary Figure 1:

Mean perioperative concentration of serum albumin (vertical bars illustrate standard deviations).

### Supplementary Figure 2:

$\Delta$ CRP (a),  $\Delta$ PCT (b) and  $\Delta$ LCT (c) on POD1 yielded AUC of 0.73, 0.63 and 0.64, respectively. The AUC of  $\Delta$ CRP on POD4 was 0.75 (d).

**Contributorship statement:**

IL involved in study design, data collection, analysis and interpretation, review of the literature, drafting and critical revision of the manuscript. GRJ involved in study design, data collection, analysis and interpretation, review of the literature, critical revision of the manuscript. AK involved in data collection, analysis and interpretation, review of the literature, critical revision of the manuscript. SM involved in data collection, analysis and interpretation, review of the literature, critical revision of the manuscript. MS involved in study design, analysis and interpretation, critical revision of the manuscript. ND involved in study design, analysis and interpretation, critical revision of the manuscript. MH study design, analysis and interpretation, drafting and critical revision of the manuscript.

**Competing interests:** There are no conflicts of interest relevant to the nature of this manuscript.

**Sources of funding:** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors

**Data sharing statement:** There is no additional data.

Figure 1: The Intensity of  $\Delta$ Alb on POD1 Correlates With the Extent of Surgery




Figure 1

254x190mm (96 x 96 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 2:  $\Delta$ Alb on POD1 Correlates With Complications (CCI) and Length of Stay (LoS)





Figure 2

254x190mm (96 x 96 DPI)

ew only


Figure 3: Receiver operating characteristic (ROC) curve of  $\Delta$ Alb on POD1







190x254mm (96 x 96 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58

**Supplementary Figure 1: Perioperative Kinetics of Serum Albumin (Alb)**







For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

116-013966 on 8 April 2017. Downloaded from <http://bmjopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

Supplementary Table 1: Correlations of the candidate biomarkers with outcomes.

|            |         | mE-PASS |                  | Minor (I-II) |              | Major (III-V) |                  | Overall complication |                  | CCI     |                  | LoS     |                  |
|------------|---------|---------|------------------|--------------|--------------|---------------|------------------|----------------------|------------------|---------|------------------|---------|------------------|
|            |         | Pearson | p-value          | Spearman     | p-value      | Spearman      | p-value          | Spearman             | p-value          | Pearson | p-value          | Pearson | p-value          |
| <b>CRP</b> | Δ Max   | 0.062   | 0.530            | 0.256        | <b>0.003</b> | 0.387         | <b>&lt;0.001</b> | 0.534                | <b>&lt;0.001</b> | 0.529   | <b>&lt;0.001</b> | 0.484   | <b>&lt;0.001</b> |
|            | Δ POD 0 | 0.052   | 0.693            | 0.070        | 0.566        | 0.049         | 0.686            | 0.098                | 0.417            | 0.231   | 0.052            | 0.381   | <b>0.001</b>     |
|            | Δ POD 1 | 0.116   | 0.256            | 0.207        | <b>0.024</b> | 0.273         | <b>0.003</b>     | 0.395                | <b>&lt;0.001</b> | 0.469   | <b>&lt;0.001</b> | 0.462   | <b>&lt;0.001</b> |
| <b>Alb</b> | Δ Max   | 0.323   | <b>0.001</b>     | 0.264        | <b>0.003</b> | 0.345         | <b>&lt;0.001</b> | 0.470                | <b>&lt;0.001</b> | 0.373   | <b>&lt;0.001</b> | 0.358   | <b>&lt;0.001</b> |
|            | Δ POD 0 | 0.479   | <b>&lt;0.001</b> | 0.298        | <b>0.006</b> | 0.194         | 0.077            | 0.420                | <b>&lt;0.001</b> | 0.302   | <b>0.005</b>     | 0.259   | <b>0.018</b>     |
|            | Δ POD 1 | 0.275   | <b>0.010</b>     | 0.228        | <b>0.016</b> | 0.372         | <b>&lt;0.001</b> | 0.485                | <b>&lt;0.001</b> | 0.383   | <b>&lt;0.001</b> | 0.468   | <b>&lt;0.001</b> |
| <b>PCT</b> | Δ Max   | -0.050  | 0.656            | 0.240        | <b>0.016</b> | 0.181         | 0.071            | 0.339                | <b>0.001</b>     | 0.140   | 0.162            | 0.204   | <b>0.040</b>     |
|            | Δ POD 0 | 0.017   | 0.906            | 0.171        | 0.204        | 0.076         | 0.570            | 0.211                | 0.112            | 0.015   | 0.909            | 0.168   | 0.206            |
|            | Δ POD 1 | -0.010  | 0.933            | 0.135        | 0.216        | 0.150         | 0.165            | 0.220                | <b>0.041</b>     | -0.034  | 0.752            | 0.103   | 0.342            |
| <b>LCT</b> | Δ Max   | 0.269   | <b>0.013</b>     | 0.301        | <b>0.003</b> | 0.196         | 0.057            | 0.426                | <b>&lt;0.001</b> | 0.317   | <b>0.002</b>     | 0.327   | <b>0.001</b>     |
|            | Δ POD 0 | 0.244   | <b>0.039</b>     | 0.297        | <b>0.007</b> | 0.178         | 0.111            | 0.412                | <b>&lt;0.001</b> | 0.299   | <b>0.007</b>     | 0.292   | <b>0.008</b>     |
|            | Δ POD 1 | 0.118   | 0.331            | 0.265        | <b>0.018</b> | 0.026         | 0.817            | 0.248                | <b>0.026</b>     | 0.193   | 0.087            | 0.104   | 0.360            |

Complications are graded according to the Clavien classification (grade I to V); mE-PASS: Modified Estimation of Physiologic Ability and Surgical Stress; CCI: Comprehensive complication index; LoS: Length of stay; CRP: C-reactive protein; Alb: Serum albumin; PCT: Procalcitonin; LCT: Lactates; Δ Max: Maximal difference between the pre- and post-operative values; Δ POD 0: Difference of concentration on POD -1 and POD 0; Δ Pod 1: Difference of concentration on POD -1 and POD 1

Supplementary Table 2: Discriminatory ability of albumin decrease on POD1

|                      | $\Delta$ Alb POD1 |               | p-value          |
|----------------------|-------------------|---------------|------------------|
|                      | <10 g/L           | $\geq$ 10 g/L |                  |
|                      | n (%)             | n (%)         |                  |
| <b>Complications</b> |                   |               |                  |
| Minor (I-II)         | 8 (15)            | 21 (36)       | <b>0.011</b>     |
| Major (III-V)        | 3 (6)             | 16 (28)       | <b>0.002</b>     |
| Overall              | 11 (20)           | 37 (64)       | <b>&lt;0.001</b> |
| CCI                  | 0                 | 20.9 (0-33.5) | <b>&lt;0.001</b> |
| <b>LoS</b>           | 4 (4-7)           | 13 (13-21)    | <b>&lt;0.001</b> |

Complications are graded according to the Clavien classification (grade I to V);  $\Delta$ Alb POD1: The difference between serum albumin concentration on POD -1 and POD 1 (g/L); mE-PASS: Modified Estimation of Physiologic Ability and Surgical Stress; CCI: Comprehensive complication index; LoS: Length of stay

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

| Section/Topic             | Item # | Recommendation   | Reported on page # |
|---------------------------|--------|--|--------------------|
| Title and abstract        | 1      | (a) Indicate the study’s design with a commonly used term in the title or the abstract   | 1                  |
|                           |        | (b) Provide in the abstract an informative and balanced summary of what was done and what was found  | 2                  |
| <b>Introduction</b>       |        |  |                    |
| Background/rationale      | 2      | Explain the scientific background and rationale for the investigation being reported   | 4                  |
| Objectives                | 3      | State specific objectives, including any prespecified hypotheses   | 4                  |
| <b>Methods</b>            |        |  |                    |
| Study design              | 4      | Present key elements of study design early in the paper  | 5                  |
| Setting                   | 5      | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection  | 5                  |
| Participants              | 6      | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up   | 5                  |
|                           |        | (b) For matched studies, give matching criteria and number of exposed and unexposed  | Not applicable     |
| Variables                 | 7      | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable   | 5-6                |
| Data sources/ measurement | 8*     | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 5-6                |
| Bias                      | 9      | Describe any efforts to address potential sources of bias  | 5-6                |
| Study size                | 10     | Explain how the study size was arrived at  | 5                  |
| Quantitative variables    | 11     | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why   | 5-6                |
| Statistical methods       | 12     | (a) Describe all statistical methods, including those used to control for confounding  | 6                  |
|                           |        | (b) Describe any methods used to examine subgroups and interactions  | 6                  |
|                           |        | (c) Explain how missing data were addressed  | 6                  |
|                           |        | (d) If applicable, explain how loss to follow-up was addressed   | Not applicable     |
|                           |        | (e) Describe any sensitivity analyses  | 6                  |

|                          |     |  |                |
|--------------------------|-----|--|----------------|
| <b>Results</b>           |     |  |                |
| Participants             | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed            | 7              |
|                          |     | (b) Give reasons for non-participation at each stage   | 7              |
|                          |     | (c) Consider use of a flow diagram   | Not applicable |
| Descriptive data         | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders   | 7              |
|                          |     | (b) Indicate number of participants with missing data for each variable of interest  | 16             |
|                          |     | (c) Summarise follow-up time (eg, average and total amount)  | 8              |
| Outcome data             | 15* | Report numbers of outcome events or summary measures over time   | 7-8            |
| Main results             | 16  | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 8              |
|                          |     | (b) Report category boundaries when continuous variables were categorized  | 6              |
|                          |     | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period   | Not applicable |
| Other analyses           | 17  | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses   | 8              |
| <b>Discussion</b>        |     |  |                |
| Key results              | 18  | Summarise key results with reference to study objectives   | 9              |
| <b>Limitations</b>       |     |  |                |
| Interpretation           | 20  | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence                                   | 10             |
| Generalisability         | 21  | Discuss the generalisability (external validity) of the study results  | 11             |
| <b>Other information</b> |     |  |                |
| Funding                  | 22  | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based  | 20             |

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

# BMJ Open

## Assessing Postoperative Decrease of Serum Albumin as an Early Predictor of Complications After Major Abdominal Surgery: A Prospective Cohort Study in a Western Center

|                                 |  |
|---------------------------------|--|
| Journal:                        | <i>BMJ Open</i>  |
| Manuscript ID                   | bmjopen-2016-013966.R2   |
| Article Type:                   | Research   |
| Date Submitted by the Author:   | 19-Jan-2017  |
| Complete List of Authors:       | Labgaa, Ismail; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Joliat, Gaëtan-Romain ; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Kefleyesus, Amanuel; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Mantziari, Styliani; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Schäfer, Markus; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Demartines, Nicolas; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>HUBNER, Martin; University Hospital of Lausanne (CHUV), Department of Visceral Surgery |
| <b>Primary Subject Heading</b>: | Surgery  |
| Secondary Subject Heading:      | Surgery  |
| Keywords:                       | Biomarker, albumin, major surgery, postoperative complications, stress response  |
|                                 |  |

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

*Research Article*

**Assessing Postoperative Decrease of Serum Albumin as an Early Predictor of Complications After Major Abdominal Surgery: A Prospective Cohort Study in a Western Center**

Ismail Labгаа<sup>1\*</sup>, Gaëtan-Romain Joliat<sup>1\*</sup>, Amanuel Kefleyesus<sup>1</sup>, Styliani Mantziari<sup>1</sup>, Markus Schäfer<sup>1</sup>, Nicolas Demartines<sup>1</sup>, Martin Hübner<sup>1</sup>

<sup>1</sup> Department of Visceral Surgery, Lausanne University Hospital CHUV, Switzerland

\* Equal contribution

**Corresponding author:**

Nicolas Demartines, MD, FACS, FRCS

Professor and Chairman

Department of visceral surgery

University Hospital CHUV

1011 Lausanne, Switzerland

Phone: +41 21 314 24 00 / Fax: +41 21 314 24 11

E-mail: [demartines@chuv.ch](mailto:demartines@chuv.ch)

The present study was presented at the 103<sup>rd</sup> Congress of Swiss Surgery (June 2016, Lugano, Switzerland) and at the Clinical Congress of the American College of Surgeons (October 2016, Washington, DC, USA).

**Key words:** Biomarker; albumin; major surgery; postoperative complications; stress response

**Word count:** 3106

## ABSTRACT

**Objective:** To test postoperative serum albumin drop ( $\Delta$ Alb) as a marker of surgical stress response and early predictor of clinical outcomes.

**Design:** Prospective cohort study (NCT02356484). Albumin was prospectively measured in 138 patients undergoing major abdominal surgery. Blood samples were collected before surgery and on postoperative days 0, 1, 2, and 3.  $\Delta$ Alb was compared to the *Modified Estimation of Physiologic Ability and Surgical Stress* (mE-PASS) score and correlated to the performances of C-reactive protein (CRP), procalcitonin (PCT), and lactate (LCT). Postoperative outcomes were postoperative complications according to both Clavien classification and Comprehensive Complication Index (CCI), and length of hospital stay (LoS).

**Setting:** Department of abdominal surgery in a European tertiary center.

**Participants:** Adult patients undergoing elective major abdominal surgery, with anticipated duration  $\geq 2$ h. Patients on immunosuppressive or antibiotic treatments before surgery were excluded.

**Results:** The level of serum albumin rapidly dropped after surgery.  $\Delta$ Alb correlated to the mE-PASS score ( $r=0.275$ ,  $p=0.01$ ) and to CRP increase ( $r=0.536$ ,  $p<0.001$ ).  $\Delta$ Alb also correlated to overall complications ( $r=0.485$ ,  $p<0.001$ ), CCI ( $r=0.383$ ,  $p<0.001$ ) and LoS ( $r=0.468$ ,  $p<0.001$ ). A  $\Delta$ Alb  $\geq 10$  g/L yielded a sensitivity of 77.1% and a specificity of 67.2% (AUC: 78.3%) to predict complications. Patients with  $\Delta$ Alb  $\geq 10$ g/l on POD 1 showed a 3 fold increased risk of overall postoperative complications.

**Conclusion:**  $\Delta$ Alb correlated to the extent of surgery and to other biological stress markers.  $\Delta$ Alb  $\geq 10$  g/L on POD 1 appears to be a promising early predictor of postoperative complications.



## STRENGTHS AND LIMITATIONS OF THE STUDY

- The present study has a prospective design and offers a head-to-head comparison with biomarkers currently used in clinical practice (C-Reactive Protein and Procalcitonin).
- Albumin drop was thoroughly assessed by analyzing its correlation with a comprehensive panel of surrogate markers for surgical trauma and validated scores for outcomes.
- The predictive value of combined biomarkers was not assessed in the present study.
- This study involved a single center and included a training cohort, without validation cohort.

## INTRODUCTION

Abdominal surgery is among the most frequently performed elective surgery<sup>1</sup>. Although surgical and perioperative improvements have reduced postoperative mortality over the last decades, postoperative morbidity has remained high<sup>2</sup>. In addition to the morbidity which patients are exposed to, postoperative complications pose a significant financial burden, while important efforts are currently pursued to reduce health care expenditures<sup>2</sup>.

The magnitude of metabolic stress response mirrors the extent of surgery<sup>3 4</sup> and presumably contributes to the risk of developing postoperative complications<sup>5 6</sup>. Early identification of patients at risk may improve outcomes, since measures to attenuate the surgical stress response and to reduce morbidity exist<sup>7</sup>.

Although C-reactive protein (CRP) and procalcitonin (PCT) have been proposed as predictors for adverse outcomes in colorectal surgery, they both display the critical limitation of slow kinetics<sup>8 9</sup>. Conversely, serum albumin (Alb) is a maintenance protein that is rapidly downregulated by inflammatory signals<sup>4 10</sup>. Preliminary data suggested that Alb level rapidly dropped after surgery and correlated to outcomes in esophageal<sup>11</sup>, oral cancer<sup>12</sup>, abdominal<sup>4</sup>, pancreatic<sup>13</sup>, liver resection<sup>14</sup>/transplant<sup>15</sup> and cardiac<sup>16</sup> surgeries. However, prospective validation is missing and Alb is not used to assess surgical stress or to predict outcomes.

This study aimed to test the hypotheses that early postoperative albumin drop (I) reflects the magnitude of surgical trauma, (II) correlates to established markers of metabolic stress, and (III) predicts postoperative complications.

## METHODS

### Study design and patient groups

This prospective study was conducted at the Department for Visceral Surgery at the University Hospital of Lausanne Switzerland (CHUV) between February and December 2015 (NCT02356484). The study was approved by the Institutional Review Board (N°367/15) and all patients provided written consent prior to surgery. Inclusion criteria were age >18 years, and elective major abdominal surgery - defined as an operative procedure with anticipated duration  $\geq 2$ h<sup>17</sup>. Perioperative care closely adhered to recently published enhanced recovery guidelines (<http://erassociety.org.loopiadns.com/guidelines/list-of-guidelines>). Standardized fluid administration was followed by advanced hemodynamic monitoring to avoid intraoperative fluid overload. According to the clinical care pathway, intravenous fluid was typically discontinued the morning after surgery.

Demographics, comorbidities, surgical details and clinical outcomes were prospectively collected and anonymized in a computerized protected database. A two-sample t-test was used to calculate sample size, with size effect of 0.8, power of 0.99 and significance level of 0.05. This determined a required number of 50 patients per group (i.e. with complication vs. without complication). Anticipating a complication rate of 40%, the final sample size for this study was n=125 patients. In order to adjust for 10% drop-out or missing data, final sample size resulted in n=138.

### Extent of surgery

The amplitude of surgical stress was measured by the *Modified Estimation of Physiologic Ability and Surgical Stress* (mE-PASS). Briefly, mE-PASS score encompasses 7 items (6 preoperative variables and the surgical procedure). It predicts the in-hospital mortality and the 30-day mortality rates, respectively<sup>18</sup>. Type of surgery, operative time, and surgical approach (open vs. laparoscopic) were recorded. Conversions from laparoscopy to laparotomy were counted as

1  
2 laparoscopic cases. Anesthesiologists and surgeons jointly estimated blood loss by measuring the  
3  
4 volume of aspirated fluid and soaked gauzes.  
5  
6  
7

### 8 9 **Biological markers**

10  
11 Serum levels of albumin, CRP, PCT and lactate (LCT) were perioperatively measured in a  
12  
13 fasting state, following standardized institutional guidelines. Blood samples were drawn the day  
14  
15 before surgery, the day of surgery (4-6 hours after the end of the operation) and on the first, second  
16  
17 and third postoperative day. As baseline values tend to show large variations especially for  
18  
19 albumin<sup>4 10</sup>, we considered that a dynamic value (difference between two time-points) might be  
20  
21 more informative than a snapshot value. Several values based on pre- and post-operative  
22  
23 concentrations, were thus calculated for each marker (i.e.,  $\Delta$  Max: Maximal difference between the  
24  
25 pre- and post-operative values;  $\Delta$  POD 0: Difference of concentration on POD -1 and POD 0;  $\Delta$   
26  
27 POD 1: Difference of concentration on POD -1 and POD 1).  
28  
29  
30  
31  
32

### 33 34 **Outcome measures**

35  
36 Complications were graded with the Clavien classification within 30 postoperative days,  
37  
38 counting grade I/II events as minor complications and grade III-V as major complications<sup>19</sup>. Every  
39  
40 complication was documented. Global morbidity for each patient was quantified by the  
41  
42 Comprehensive Complication Index (CCI) on a scale from 0 to 100<sup>20</sup>, representing respectively no  
43  
44 complication and postoperative death. Length of stay (LoS) was considered as the duration from  
45  
46 the day of surgery until discharge.  
47  
48  
49  
50

### 51 52 **Statistical analysis**

53  
54 Continuous variables were presented as mean with standard deviation (SD) or median value  
55  
56 with interquartile range (IQR) depending on the normality of the distribution and compared using  
57  
58 Student's *t* test and Mann-Whitney U test, whereas categorical variables were given as frequencies  
59  
60

1  
2 with percentages and compared with chi-square test. For statistical analyses, the following  
3  
4 parameters were dichotomized: age ( $\geq 70$  years), body-mass index ( $\geq 25$  kg/m<sup>2</sup>), operative time  
5  
6 ( $\geq 180$  minutes), and blood loss ( $\geq 200$  ml). Spearman's and Pearson's tests were used to measure  
7  
8 correlations of categorical ( $\rho$ ) and continuous ( $r$ ) variables, respectively. Receiver operating  
9  
10 characteristic (ROC) curves were applied to obtain the area under the curve (AUC), and to  
11  
12 determine ideal cut-offs. Logistic regression was applied to identify independent predictors;  
13  
14 variables with significance  $< 0.1$  in univariable analyses were further included in multivariable  
15  
16 analyses. A p value  $< 0.05$  was considered to be statistically significant in all tests. Data analyses  
17  
18 were generated using SPSS v20 statistical software (Chicago, IL).  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

### Patients Characteristics, Details of Surgery, and Outcomes

During the study period, 155 consecutive patients undergoing major abdominal surgery were potentially eligible for inclusion, but 17 of them refused to participate. As a result, 138 patients were included in the study and had a complete follow-up. Demographics and surgical details are displayed in **Table 1**. Median mE-PASS score was 0.66 (IQR 0.45-0.96).

Overall, 60/138 patients (43%) experienced at least one complication, and one patient died after total gastrectomy and splenopancreatectomy due to cardiorespiratory arrest. Minor and major complications were observed in 35 and 25 patients, respectively. Patients showed a mean CCI of 13.2 (SD 18.5), and were discharged after a median LoS of 8 days (IQR 5-15 days).

### Perioperative Profile of Biomarkers

The perioperative profile of albumin showed a rapid drop induced by surgery, followed by a plateau phase between POD 0 and POD 3 (**Supplementary Figure 1**). Lactate levels peaked in the first 4-6h after surgery and were back to baseline on POD1. Conversely, CRP and PCT showed slow kinetics reaching maximal values on POD 4 and 3, respectively. The mean maximal decrease of albumin was 11.3 g/L ( $\pm 5.6$ ), which was similar to albumin drop on POD 1: 10.1 g/L (SD: 5.8). Further analyses were hence focused on  $\Delta$ Alb on POD1.

### Correlation of $\Delta$ Alb to surgical stress, biomarkers, and outcomes

$\Delta$ Alb on POD1 correlated to surgical stress (mE-PASS) ( $r=0.275$ ,  $p=0.01$ ) and to surrogates such as duration of surgery ( $r=0.562$ ,  $p<0.001$ ), blood loss ( $r=0.391$ ,  $p<0.001$ ), and surgical approach ( $\rho=0.55$ ,  $p<0.001$ ) (**Figure 1**).

$\Delta$ Alb on POD1 also correlated to maximal increases of CRP ( $r=0.54$ ,  $p<0.001$ ), PCT ( $r=0.43$ ,  $p<0.001$ ), and LCT ( $r=0.25$ ,  $p=0.02$ ). Furthermore, a positive and significant correlation was highlighted between  $\Delta$ Alb on POD1 and  $\Delta$ CRP on POD4 ( $\rho=0.234$ ,  $p=0.044$ ).  $\Delta$ Alb on POD1 was



## DISCUSSION

Surgery induced a rapid decrease of serum albumin in patients undergoing elective major abdominal procedures; and it remained stable for several postoperative days. Although correlation coefficients were modest, the decrease in serum albumin significantly correlated with (I) the extent of surgery (mE-PASS, blood loss, duration of surgery, and surgical approach), (II) the maximal amplitude of other stress markers, such as CRP, PCT and LCT and (III) was consistently associated with adverse outcomes (according to both Clavien classification, CCI, and LoS). A serum albumin decrease  $\geq 10$  g/L on POD 1 was independently associated with a 3-fold increased risk for postoperative complication.

The present study tested a panel of 4 biomarkers of which 2 are routinely used and served as benchmarks (CRP and PCT) and 2 are less established markers and deserved prospective investigations (Alb and LCT). The mE-PASS accurately recapitulates surgical stress, and was validated and used in abdominal surgery<sup>18 21-24</sup>. To our knowledge, there is no other validated and available score. One study endpoint was the CCI, which is a score summing each complication graded according to the Clavien classification. As a result, CCI avoids omitting minor complications, and is therefore more accurate than the Clavien classification alone<sup>20</sup>. Serum albumin showed the more consistent correlation with stress response and clinical outcomes. Alb and LCT both display some of the features for ideal markers: easy to measure and to interpret, readily available, can be repeated for monitoring and non-expensive. While Alb rapidly dropped after surgery and subsequently stabilized until POD 3, lactate showed a prompt increase followed by a fast return to baseline value, already on POD 1. It can be assumed that the timing of blood collection may have a more important impact on LCT than on Alb. As a consequence, Alb is more robust and easier used in the clinical setting. Importantly, the selected markers were repeatedly measured, which allowed us to capture their perioperative profiles and to further calculate differences of concentrations between various time-points. The latter was revealed to be pivotal and more informative than a single value.



1  
2 The mechanisms of early postoperative albumin decrease combine altered metabolism,  
3 blood loss/dilution and most importantly redistribution into the third space, due to capillary  
4 leakage. The latter accounts for >75% of albumin decrease in the early postoperative phase and  
5  
6  
7  
8  
9 appears to be related to the magnitude of systemic inflammatory response<sup>10 25 26</sup>. Therefore,  
10  
11 albumin decrease is certainly influenced by perioperative fluid management (liberal vs. restrictive)  
12  
13  
14 but it mainly reflects the extent of postsurgical stress response.

15  
16 In multivariable analysis (table 2), 2 factors were independently associated with  
17  
18 complications: approach and  $\Delta\text{Alb POD1} \geq 10$  g/L. The overlap of certain parameters of surgical  
19  
20 stress may, in part, explain why they were not identified as independent predictors of  
21  
22 complications. It may also suggest that serum albumin mirrors these different parameters.  
23

24  
25 Some limitations need to be addressed. The present analyses were focused on 4 biomarkers  
26  
27 that are readily available and easy to evaluate in the clinical setting. This non-inclusive panel of  
28  
29 biomarkers could be perceived as a methodological shortcoming. Notwithstanding, integrating  
30  
31 more complex and costly biomarkers would unlikely be more informative given their poor  
32  
33 reproducibility, cost and assay measurement complexity. Likewise, this study did not assess the  
34  
35 predictive value of albumin drop combined with other biomarker and/or clinical variables.  
36  
37 Although such a classifier may presumably improve sensitivity and specificity, it will also be more  
38  
39 complex which could ultimately preclude its implementation in clinical practice. Blood collection  
40  
41 on POD 0 occurred 4-6 hours after the end of surgery. This delay might be long enough to alter the  
42  
43 discriminatory ability of certain biomarkers, particularly lactate<sup>27</sup>.  
44  
45

46  
47 Available data on the predictive role of postoperative Alb are scarce; and most of these  
48  
49 reports were retrospective studies<sup>11-13 16 28</sup>. Of note, each of the studies investigated only a single  
50  
51 postoperative value of serum albumin. This represents a critical drawback as it cannot be  
52  
53 discerned whether the low postoperative concentration of serum albumin resulted from intense  
54  
55 surgical stress or from low preoperative level, which is an acknowledged predictor of increased  
56  
57 postoperative complication<sup>29 30</sup>. A prospective pilot study in abdominal surgery – conducted  
58  
59  
60

1 recently in our institution- showed consistent findings, with an increased risk of complication  
2 related to the amplitude of serum albumin postoperative drop <sup>4</sup>. Of note, the cohorts from this  
3 previous study (70 patients) and from the present one (138 patients) were strictly distinct.  
4  
5  
6  
7  
8  
9 Postoperative lactate has been more thoroughly explored in liver surgery, with few reports in other  
10 surgical fields. In a recent landmark study, Vibert et al. demonstrated that a postoperative cut-off  
11 of arterial lactate > 3mmol/L at the end of surgery was an independent predictor of complications  
12 after elective hepatectomies <sup>27</sup>. Their conclusion correlates with the present findings since  $\Delta$ LCT  
13 POD0 was correlated with mE-PASS (p=0.039), overall complication (p<0.001), CCI (p=0.007)  
14 and LoS (p=0.008) (**Figure 2**). Although both CRP and PCT are routinely used biomarkers in  
15 clinical practice, they are typically contributive on POD 4 only. The present study design allowed  
16 to confirm the ultimate advantage of Alb to be up-regulated within the early postoperative phase,  
17 illustrated by the correlation between  $\Delta$ Alb on POD1 and  $\Delta$ CRP on POD4 ( $\rho=0.234$ ,  $p=0.044$ ),  
18 highlighted in this study. In fact,  $\Delta$ Alb on POD1 was more sensitive than  $\Delta$ CRP on POD4,  
19 illustrated by AUC of 0.78 and 0.75, respectively (Figure 3 and Supplementary 3D).  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 How the monitoring of Alb in surgical patients can lead to better outcomes is a key  
34 question. Measures to preoperatively attenuate the stress response to surgery have been extensively  
35 explored. Interestingly, successful attempts were reported with immunonutrition <sup>31</sup>, enhanced  
36 recovery programs (ERAS) <sup>32,33</sup>, or high-dose glucocorticoids <sup>34</sup>. Whether these options would be  
37 able to restrain the stress response, once triggered, in the early postoperative phase remains to be  
38 investigated. In this setting, albumin drop may indicate whether these measures may be beneficial  
39 in the perioperative period by being incorporated into the design of clinical trials as a marker for  
40 patients at higher risk of perioperative complications.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 In summary, early postoperative decrease of serum albumin correlated with the (I)  
52 extent of surgery, (II) its metabolic response, and with (III) adverse outcomes such as  
53 complications and length of hospital stay. A decreased concentration of serum albumin  $\geq 10$ g/l on  
54 POD 1 was associated with a 3-fold increased risk of overall postoperative complications; albumin  
55  
56  
57  
58  
59  
60

1  
2 decrease occurs rapidly after surgery and remains stable for several days. As it is easy to measure,  
3  
4 it could be used to identify patients at risk.  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**REFERENCES**

1. Noordzij PG, Poldermans D, Schouten O, et al. Postoperative mortality in The Netherlands: a population-based analysis of surgery-specific risk in adults. *Anesthesiology* 2010;**112**(5):1105-15.
2. Vonlanthen R, Slankamenac K, Breitenstein S, et al. The impact of complications on costs of major surgical procedures: a cost analysis of 1200 patients. *Ann Surg* 2011;**254**(6):907-13.
3. Thorell A, Nygren J, Ljungqvist O. Insulin resistance: a marker of surgical stress. *Curr Opin Clin Nutr Metab Care* 1999;**2**(1):69-78.
4. Mantziari S, Hubner M, Coti-Bertrand P, et al. A Novel Approach to Major Surgery: Tracking Its Pathophysiologic Footprints. *World J Surg* 2015;**39**(11):2641-51.
5. Kohl BA, Deutschman CS. The inflammatory response to surgery and trauma. *Curr Opin Crit Care* 2006;**12**(4):325-32.
6. Amar D, Zhang H, Park B, et al. Inflammation and outcome after general thoracic surgery. *Eur J Cardiothorac Surg* 2007;**32**(3):431-4.
7. Hall R. Identification of inflammatory mediators and their modulation by strategies for the management of the systemic inflammatory response during cardiac surgery. *J Cardiothorac Vasc Anesth* 2013;**27**(5):983-1033.
8. Facy O, Paquette B, Orry D, et al. Diagnostic Accuracy of Inflammatory Markers As Early Predictors of Infection After Elective Colorectal Surgery: Results From the IMACORS Study. *Ann Surg* 2016;**263**(5):961-6.
9. Giaccaglia V, Salvi PF, Antonelli MS, et al. Procalcitonin Reveals Early Dehiscence in Colorectal Surgery: The PREDICS Study. *Ann Surg* 2016;**263**(5):967-72.
10. Hubner M, Mantziari S, Demartines N, et al. Postoperative Albumin Drop Is a Marker for Surgical Stress and a Predictor for Clinical Outcome: A Pilot Study. *Gastroenterol Res Pract* 2016;**2016**:8743187.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
11. Ryan AM, Hearty A, Prichard RS, et al. Association of hypoalbuminemia on the first postoperative day and complications following esophagectomy. *J Gastrointest Surg* 2007;**11**(10):1355-60.
12. Lee JI, Kwon M, Roh JL, et al. Postoperative hypoalbuminemia as a risk factor for surgical site infection after oral cancer surgery. *Oral Dis* 2015;**21**(2):178-84.
13. Fujiwara Y, Shiba H, Shirai Y, et al. Perioperative serum albumin correlates with postoperative pancreatic fistula after pancreaticoduodenectomy. *Anticancer Res* 2015;**35**(1):499-503.
14. Labgaa I, Joliat GR, Demartines N, et al. Serum albumin is an early predictor of complications after liver surgery. *Dig Liver Dis* 2016;**48**(5):559-61.
15. Sang BH, Bang JY, Song JG, et al. Hypoalbuminemia Within Two Postoperative Days Is an Independent Risk Factor for Acute Kidney Injury Following Living Donor Liver Transplantation: A Propensity Score Analysis of 998 Consecutive Patients. *Crit Care Med* 2015;**43**(12):2552-61.
16. Lee EH, Chin JH, Choi DK, et al. Postoperative hypoalbuminemia is associated with outcome in patients undergoing off-pump coronary artery bypass graft surgery. *J Cardiothorac Vasc Anesth* 2011;**25**(3):462-8.
17. Hubner M, Cerantola Y, Grass F, et al. Preoperative immunonutrition in patients at nutritional risk: results of a double-blinded randomized clinical trial. *Eur J Clin Nutr* 2012;**66**(7):850-5.
18. Haga Y, Ikejiri K, Wada Y, et al. A multicenter prospective study of surgical audit systems. *Ann Surg* 2011;**253**(1):194-201.
19. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;**240**(2):205-13.
20. Slankamenac K, Graf R, Barkun J, et al. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. *Ann Surg* 2013;**258**(1):1-7.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
21. Haga Y, Ikejiri K, Takeuchi H, et al. Value of general surgical risk models for predicting postoperative liver failure and mortality following liver surgery. *J Surg Oncol* 2012;**106**(7):898-904.
22. Haga Y, Wada Y, Takeuchi H, et al. Evaluation of modified Estimation of Physiologic Ability and Surgical Stress in gastric carcinoma surgery. *Gastric Cancer* 2012;**15**(1):7-14.
23. Haga Y, Wada Y, Takeuchi H, et al. Evaluation of modified estimation of physiologic ability and surgical stress in patients undergoing surgery for choledochocystolithiasis. *World J Surg* 2014;**38**(5):1177-83.
24. Haga Y, Wada Y, Saitoh T, et al. Value of general surgical risk models for predicting postoperative morbidity and mortality in pancreatic resections for pancreatobiliary carcinomas. *J Hepatobiliary Pancreat Sci* 2014;**21**(8):599-606.
25. Smeets HJ, Kievit J, Dulfer FT, et al. Analysis of post-operative hypalbuminaemia: a clinical study. *Int Surg* 1994;**79**(2):152-7.
26. Fleck A, Raines G, Hawker F, et al. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. *Lancet* 1985;**1**(8432):781-4.
27. Vibert E, Boleslawski E, Cosse C, et al. Arterial Lactate Concentration at the End of an Elective Hepatectomy Is an Early Predictor of the Postoperative Course and a Potential Surrogate of Intraoperative Events. *Ann Surg* 2015;**262**(5):787-93.
28. Sang BH, Bang JY, Song JG, et al. Hypoalbuminemia Within Two Postoperative Days Is an Independent Risk Factor for Acute Kidney Injury Following Living Donor Liver Transplantation: A Propensity Score Analysis of 998 Consecutive Patients. *Crit Care Med* 2015.
29. Poon RT, Fan ST, Lo CM, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. *Ann Surg* 2004;**240**(4):698-708; discussion 08-10.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
30. Uzunoglu FG, Reeh M, Vettorazzi E, et al. Preoperative Pancreatic Resection (PREPARE) score: a prospective multicenter-based morbidity risk score. *Ann Surg* 2014;**260**(5):857-63; discussion 63-4.
31. Cerantola Y, Hubner M, Grass F, et al. Immunonutrition in gastrointestinal surgery. *Br J Surg* 2011;**98**(1):37-48.
32. Carli F. Physiologic considerations of Enhanced Recovery After Surgery (ERAS) programs: implications of the stress response. *Can J Anaesth* 2015;**62**(2):110-9.
33. Ljungqvist O, Nygren J, Soop M, et al. Metabolic perioperative management: novel concepts. *Curr Opin Crit Care* 2005;**11**(4):295-9.
34. de la Motte L, Kehlet H, Vogt K, et al. Preoperative methylprednisolone enhances recovery after endovascular aortic repair: a randomized, double-blind, placebo-controlled clinical trial. *Ann Surg* 2014;**260**(3):540-8; discussion 48-9.

**Table 1: Baseline characteristics of patients with and without postoperative complications.**

|               |                                  | Pat. with<br>complications (n=60)<br>n (%) | Pat. without<br>complications (n=78)<br>n (%) | p-value      |
|---------------|----------------------------------|--|---|--------------|
| Demographics  |                                  |  |   |              |
|               | Median age (years)*              | 64 (50-73)                                 | 59 (51-69)                                    | 0.306        |
|               | Age ≥ 70 years                   | 20 (51)                                    | 19 (49)                                       | 0.246        |
|               | Gender (male)                    | 38 (63)                                    | 34 (44)                                       | <b>0.021</b> |
|               | Median BMI (kg/m <sup>2</sup> )* | 24 (22-28)                                 | 26 (22-31)                                    | <b>0.038</b> |
|               | BMI ≥25 kg/m <sup>2</sup>        | 27 (47)                                    | 46 (60)                                       | 0.128        |
| Comorbidities |                                  |  |   |              |
|               | ASA (I-II)                       | 36 (60)                                    | 52 (67)                                       | 0.419        |
|               | ECOG (0-1)                       | 45 (75)                                    | 66 (85)                                       | 0.158        |
|               | Cirrhosis                        | 2 (3)                                      | 1 (1)   | 0.413        |
|               | Heart disease                    | 10 (17)                                    | 12 (16)                                       | 0.864        |
|               | Lung disease                     | 8 (13)                                     | 7 (9)   | 0.415        |
|               | Diabetes                         | 8 (13)                                     | 13 (17)                                       | 0.589        |
|               | History of surgery               | 33 (55)                                    | 42 (55)                                       | 0.958        |
|               | Cancer                           | 45 (75)                                    | 54 (69)                                       | 0.456        |
| Surgery       |                                  |  |   |              |
|               | Type                             |  |   |              |
|               | Colorectal                       | 14 (23)                                    | 17 (22)                                       | 0.840        |
|               | HPB                              | 31 (52)                                    | 19 (24)                                       | 0.001        |
|               | Upper-GI                         | 11 (18)                                    | 17 (22)                                       | 0.674        |
|               | Other                            | 4 (7)                                      | 25 (32)                                       | <0.001       |
|               | Approach                         |  |   | <0.001       |
|               | Open                             | 50 (83)                                    | 29 (37)                                       |              |
|               | Laparoscopy                      | 10 (17)                                    | 49 (63)                                       |              |
|               | Duration Median (min)*           | 271 (224-340)                              | 154 (112-239)                                 | <0.001       |
|               | ≥ 180 min                        | 46 (77)                                    | 33 (42)                                       | <0.001       |
|               | Blood Loss Median (mL)*          | 300 (100-575)                              | 90 (0-263)                                    | 0.002        |
|               | ≥ 200 mL                         | 40 (67)                                    | 24 (31)                                       | <0.001       |
|               | Median mE-PASS                   | 0.77 (0.57-1.03)                           | 0.49 (0.4-0.81)                               | 0.12         |

BMI: Body mass index; ASA: American Association of Anesthesiologists physical status classification system; ECOG: Eastern Cooperative Oncology Group performance status; cancer: operative indication; HPB: Hepato-Pancreatico-Biliary surgery; Upper-GI: Upper-Gastrointestinal surgery; mE-PASS: Modified Estimation of Physiologic Ability and Surgical Stress; CCI: Comprehensive complication index; LoS: Length of stay. Other surgeries included pressurized intra-abdominal aerosol chemotherapy (17), endocrine operations (4), complex abdominal wall operations (2), resections of retroperitoneal sarcomas (3), nephrectomy (1), and interrupted limb perfusions for melanoma (2). \* Median values (IQR)



**Table 2: Logistic regression with uni- and multivariable analysis for predictors of postoperative complications.**

|                                 | Overall postoperative complications |            |                  |               |            |              |
|---------------------------------|-------------------------------------|------------|------------------|---------------|------------|--------------|
|                                 | Univariable                         |            |                  | Multivariable |            |              |
|                                 | OR                                  | 95% CI     | p-value          | OR            | 95% CI     | p-value      |
| Age $\geq$ 70 years             | 1.55                                | 0.74-3.27  | 0.247            |               |            |              |
| Gender (Female)                 | 0.45                                | 0.22-0.89  | <b>0.022</b>     | 1.06          | 0.38-2.96  | 0.905        |
| ASA I/II                        | 1.33                                | 0.66-2.68  | 0.42             |               |            |              |
| ECOG 0/1                        | 1.83                                | 0.79-4.28  | 0.161            |               |            |              |
| Cirrhosis                       | 2.66                                | 0.24-30    | 0.43             |               |            |              |
| Cancer                          | 1.33                                | 0.63-2.84  | 0.456            |               |            |              |
| Diabetes                        | 0.77                                | 0.3-2      | 0.59             |               |            |              |
| BMI $\geq$ 25 kg/m <sup>2</sup> | 0.59                                | 0.3-1.17   | 0.129            |               |            |              |
| Approach (open)                 | 8.49                                | 3.72-19.18 | <b>&lt;0.001</b> | 11.22         | 2.74-46.05 | <b>0.001</b> |
| Duration $\geq$ 180 min         | 4.48                                | 2.12-9.47  | <b>&lt;0.001</b> | 0.47          | 0.11-1.94  | 0.297        |
| Blood loss $\geq$ 200 mL        | 4.50                                | 2.19-9.25  | <b>&lt;0.001</b> | 1.68          | 0.57-4.99  | 0.350        |
| $\Delta$ Alb POD1 $\geq$ 10 g/L | 6.89                                | 2.94-16.14 | <b>&lt;0.001</b> | 3.29          | 1.14-9.49  | <b>0.028</b> |

ASA: American Association of Anesthesiologists physical status classification system; ECOG: Eastern Cooperative Oncology Group performance status; BMI: Body mass index;  $\Delta$ Alb POD1: The difference between serum albumin concentration on POD -1 and POD 1 (g/L). OR: odds ratio

## LEGENDS

### Figure 1:

$\Delta$ Alb on POD1 correlates with the extent of surgery.  $\Delta$ Alb on POD1 showed a significant correlation with (a) mE-PASS ( $r=0.275$ ,  $p=0.01$ ), (b) blood loss ( $r=0.391$ ,  $p<0.001$ ), and (c) duration of surgery ( $r=0.562$ ,  $p<0.001$ ).

### Figure 2:

The postoperative decrease of Alb on POD 1 correlated with outcomes.  $\Delta$ Alb on POD1 showed a significant correlation with CCI (Comprehensive complication index) (a), and with length of stay (LoS) (b).

### Figure 3:

Receiver operating characteristic (ROC) curve to determine the optimal cut-off of  $\Delta$ Alb on POD1 (blue line), showed an AUC of 0.78.

### Supplementary Figure 1:

Mean perioperative concentration of serum albumin (vertical bars illustrate standard deviations).

### Supplementary Figure 2:

$\Delta$ CRP (a),  $\Delta$ PCT (b) and  $\Delta$ LCT (c) on POD1 yielded AUC of 0.73, 0.63 and 0.64, respectively. The AUC of  $\Delta$ CRP on POD4 was 0.75 (d).

**Contributorship statement:**

IL involved in study design, data collection, analysis and interpretation, review of the literature, drafting and critical revision of the manuscript. GRJ involved in study design, data collection, analysis and interpretation, review of the literature, critical revision of the manuscript. AK involved in data collection, analysis and interpretation, review of the literature, critical revision of the manuscript. SM involved in data collection, analysis and interpretation, review of the literature, critical revision of the manuscript. MS involved in study design, analysis and interpretation, critical revision of the manuscript. ND involved in study design, analysis and interpretation, critical revision of the manuscript. MH study design, analysis and interpretation, drafting and critical revision of the manuscript.

**Competing interests:** There are no conflicts of interest relevant to the nature of this manuscript.

**Sources of funding:** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors

**Data sharing statement:** There is no additional data.

Figure 1: The Intensity of  $\Delta$ Alb on POD1 Correlates With the Extent of Surgery




Figure 1

254x190mm (300 x 300 DPI)

ew only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 2: ΔAlb on POD1 Correlates With Complications (CCI) and Length of Stay (LoS)




Figure 2

254x190mm (300 x 300 DPI)

ew only

Figure 3: Receiver operating characteristic (ROC) curve of  $\Delta$ Alb on POD1





Figure 3

254x190mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


**Supplementary Figure 1: Perioperative Kinetics of Serum Albumin (Alb)**



254x190mm (300 x 300 DPI)

ew only

Supplementary Figure 2: Receiver operating characteristic (ROC) curves of other stress markers



254x190mm (300 x 300 DPI)

ew only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Supplementary Table 1: Correlations of the candidate biomarkers with outcomes.

|            |         | mE-PASS |                  | Minor (I-II) |              | Major (III-V) |                  | Overall complication |                  | CCI     |                  | LoS     |                  |
|------------|---------|---------|------------------|--------------|--------------|---------------|------------------|----------------------|------------------|---------|------------------|---------|------------------|
|            |         | Pearson | p-value          | Spearman     | p-value      | Spearman      | p-value          | Spearman             | p-value          | Pearson | p-value          | Pearson | p-value          |
| <b>CRP</b> | Δ Max   | 0.062   | 0.530            | 0.256        | <b>0.003</b> | 0.387         | <b>&lt;0.001</b> | 0.534                | <b>&lt;0.001</b> | 0.529   | <b>&lt;0.001</b> | 0.484   | <b>&lt;0.001</b> |
|            | Δ POD 0 | 0.052   | 0.693            | 0.070        | 0.566        | 0.049         | 0.686            | 0.098                | 0.417            | 0.231   | 0.052            | 0.381   | <b>0.001</b>     |
|            | Δ POD 1 | 0.116   | 0.256            | 0.207        | <b>0.024</b> | 0.273         | <b>0.003</b>     | 0.395                | <b>&lt;0.001</b> | 0.469   | <b>&lt;0.001</b> | 0.462   | <b>&lt;0.001</b> |
| <b>Alb</b> | Δ Max   | 0.323   | <b>0.001</b>     | 0.264        | <b>0.003</b> | 0.345         | <b>&lt;0.001</b> | 0.470                | <b>&lt;0.001</b> | 0.373   | <b>&lt;0.001</b> | 0.358   | <b>&lt;0.001</b> |
|            | Δ POD 0 | 0.479   | <b>&lt;0.001</b> | 0.298        | <b>0.006</b> | 0.194         | 0.077            | 0.420                | <b>&lt;0.001</b> | 0.302   | <b>0.005</b>     | 0.259   | <b>0.018</b>     |
|            | Δ POD 1 | 0.275   | <b>0.010</b>     | 0.228        | <b>0.016</b> | 0.372         | <b>&lt;0.001</b> | 0.485                | <b>&lt;0.001</b> | 0.383   | <b>&lt;0.001</b> | 0.468   | <b>&lt;0.001</b> |
| <b>PCT</b> | Δ Max   | -0.050  | 0.656            | 0.240        | <b>0.016</b> | 0.181         | 0.071            | 0.339                | <b>0.001</b>     | 0.140   | 0.162            | 0.204   | <b>0.040</b>     |
|            | Δ POD 0 | 0.017   | 0.906            | 0.171        | 0.204        | 0.076         | 0.570            | 0.211                | 0.112            | 0.015   | 0.909            | 0.168   | 0.206            |
|            | Δ POD 1 | -0.010  | 0.933            | 0.135        | 0.216        | 0.150         | 0.165            | 0.220                | <b>0.041</b>     | -0.034  | 0.752            | 0.103   | 0.342            |
| <b>LCT</b> | Δ Max   | 0.269   | <b>0.013</b>     | 0.301        | <b>0.003</b> | 0.196         | 0.057            | 0.426                | <b>&lt;0.001</b> | 0.317   | <b>0.002</b>     | 0.327   | <b>0.001</b>     |
|            | Δ POD 0 | 0.244   | <b>0.039</b>     | 0.297        | <b>0.007</b> | 0.178         | 0.111            | 0.412                | <b>&lt;0.001</b> | 0.299   | <b>0.007</b>     | 0.292   | <b>0.008</b>     |
|            | Δ POD 1 | 0.118   | 0.331            | 0.265        | <b>0.018</b> | 0.026         | 0.817            | 0.248                | <b>0.026</b>     | 0.193   | 0.087            | 0.104   | 0.360            |

Complications are graded according to the Clavien classification (grade I to V); mE-PASS: Modified Estimation of Physiologic Ability and Surgical Stress; CCI: Comprehensive complication index; LoS: Length of stay; CRP: C-reactive protein; Alb: Serum albumin; PCT: Procalcitonin; LCT: Lactates; Δ Max: Maximal difference between the pre- and post-operative values; Δ POD 0: Difference of concentration on POD -1 and POD 0; Δ Pod 1: Difference of concentration on POD -1 and POD 1

Supplementary Table 2: Discriminatory ability of albumin decrease on POD1

|                      | $\Delta$ Alb POD1 |               | p-value          |
|----------------------|-------------------|---------------|------------------|
|                      | <10 g/L           | $\geq$ 10 g/L |                  |
|                      | n (%)             | n (%)         |                  |
| <b>Complications</b> |                   |               |                  |
| Minor (I-II)         | 8 (15)            | 21 (36)       | <b>0.011</b>     |
| Major (III-V)        | 3 (6)             | 16 (28)       | <b>0.002</b>     |
| Overall              | 11 (20)           | 37 (64)       | <b>&lt;0.001</b> |
| CCI                  | 0                 | 20.9 (0-33.5) | <b>&lt;0.001</b> |
| <b>LoS</b>           | 4 (4-7)           | 13 (13-21)    | <b>&lt;0.001</b> |

Complications are graded according to the Clavien classification (grade I to V);  $\Delta$ Alb POD1: The difference between serum albumin concentration on POD -1 and POD 1 (g/L); mE-PASS: Modified Estimation of Physiologic Ability and Surgical Stress; CCI: Comprehensive complication index; LoS: Length of stay

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

| Section/Topic                | Item # | Recommendation   | Reported on page # |
|------------------------------|--------|--|--------------------|
| Title and abstract           | 1      | (a) Indicate the study's design with a commonly used term in the title or the abstract   | 1                  |
|                              |        | (b) Provide in the abstract an informative and balanced summary of what was done and what was found  | 2                  |
| <b>Introduction</b>          |        |  |                    |
| Background/rationale         | 2      | Explain the scientific background and rationale for the investigation being reported   | 4                  |
| Objectives                   | 3      | State specific objectives, including any prespecified hypotheses   | 4                  |
| <b>Methods</b>               |        |  |                    |
| Study design                 | 4      | Present key elements of study design early in the paper  | 5                  |
| Setting                      | 5      | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection  | 5                  |
| Participants                 | 6      | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up   | 5                  |
|                              |        | (b) For matched studies, give matching criteria and number of exposed and unexposed  | Not applicable     |
| Variables                    | 7      | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable   | 5-6                |
| Data sources/<br>measurement | 8*     | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 5-6                |
| Bias                         | 9      | Describe any efforts to address potential sources of bias  | 5-6                |
| Study size                   | 10     | Explain how the study size was arrived at  | 5                  |
| Quantitative variables       | 11     | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why   | 5-6                |
| Statistical methods          | 12     | (a) Describe all statistical methods, including those used to control for confounding  | 6                  |
|                              |        | (b) Describe any methods used to examine subgroups and interactions  | 6                  |
|                              |        | (c) Explain how missing data were addressed  | 6                  |
|                              |        | (d) If applicable, explain how loss to follow-up was addressed   | Not applicable     |
|                              |        | (e) Describe any sensitivity analyses  | 6                  |

| <b>Results</b>           |     |  |                |
|--------------------------|-----|--|----------------|
| Participants             | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed            | 7              |
|                          |     | (b) Give reasons for non-participation at each stage   | 7              |
|                          |     | (c) Consider use of a flow diagram   | Not applicable |
| Descriptive data         | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders   | 7              |
|                          |     | (b) Indicate number of participants with missing data for each variable of interest  | 16             |
|                          |     | (c) Summarise follow-up time (eg, average and total amount)  | 8              |
| Outcome data             | 15* | Report numbers of outcome events or summary measures over time   | 7-8            |
| Main results             | 16  | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 8              |
|                          |     | (b) Report category boundaries when continuous variables were categorized  | 6              |
|                          |     | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period   | Not applicable |
| Other analyses           | 17  | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses   | 8              |
| <b>Discussion</b>        |     |  |                |
| Key results              | 18  | Summarise key results with reference to study objectives   | 9              |
| <b>Limitations</b>       |     |  |                |
| Interpretation           | 20  | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence                                   | 10             |
| Generalisability         | 21  | Discuss the generalisability (external validity) of the study results  | 11             |
| <b>Other information</b> |     |  |                |
| Funding                  | 22  | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based  | 20             |

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

# BMJ Open

## Is postoperative decrease of serum albumin an early predictor of complications after major abdominal surgery? A prospective cohort study in a European centre

|                                 |  |
|---------------------------------|--|
| Journal:                        | <i>BMJ Open</i>  |
| Manuscript ID                   | bmjopen-2016-013966.R3   |
| Article Type:                   | Research   |
| Date Submitted by the Author:   | 10-Feb-2017  |
| Complete List of Authors:       | Labгаа, Ismail; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Joliat, Gaëtan-Romain ; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Kefleyesus, Amanuel; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Mantziari, Styliani; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Schäfer, Markus; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>Demartines, Nicolas; University Hospital of Lausanne (CHUV), Department of Visceral Surgery<br>HUBNER, Martin; University Hospital of Lausanne (CHUV), Department of Visceral Surgery |
| <b>Primary Subject Heading</b>: | Surgery  |
| Secondary Subject Heading:      | Surgery  |
| Keywords:                       | Biomarker, albumin, major surgery, postoperative complications, stress response  |
|                                 |  |

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

*Research Article*

**Is postoperative decrease of serum albumin an early predictor of complications after major abdominal surgery? A prospective cohort study in a European centre**

Ismail Labgaa<sup>1\*</sup>, Gaëtan-Romain Joliat<sup>1\*</sup>, Amanuel Kefleyesus<sup>1</sup>, Styliani Mantziari<sup>1</sup>, Markus Schäfer<sup>1</sup>, Nicolas Demartines<sup>1</sup>, Martin Hübner<sup>1</sup>

<sup>1</sup> Department of Visceral Surgery, Lausanne University Hospital CHUV, Switzerland

\* Equal contribution

**Corresponding author:**

Nicolas Demartines, MD, FACS, FRCS

Professor and Chairman

Department of visceral surgery

University Hospital CHUV

1011 Lausanne, Switzerland

Phone: +41 21 314 24 00 / Fax: +41 21 314 24 11

E-mail: [demartines@chuv.ch](mailto:demartines@chuv.ch)

The present study was presented at the 103<sup>rd</sup> Congress of Swiss Surgery (June 2016, Lugano, Switzerland) and at the Clinical Congress of the American College of Surgeons (October 2016, Washington, DC, USA).

**Key words:** Biomarker; albumin; major surgery; postoperative complications; stress response

**Word count:** 3106

## ABSTRACT

**Objective:** To test postoperative serum albumin drop ( $\Delta$ Alb) as a marker of surgical stress response and early predictor of clinical outcomes.

**Design:** Prospective cohort study (NCT02356484). Albumin was prospectively measured in 138 patients undergoing major abdominal surgery. Blood samples were collected before surgery and on postoperative days 0, 1, 2, and 3.  $\Delta$ Alb was compared to the *Modified Estimation of Physiologic Ability and Surgical Stress* (mE-PASS) score and correlated to the performances of C-reactive protein (CRP), procalcitonin (PCT), and lactate (LCT). Postoperative outcomes were postoperative complications according to both Clavien classification and Comprehensive Complication Index (CCI), and length of hospital stay (LoS).

**Setting:** Department of abdominal surgery in a European tertiary center.

**Participants:** Adult patients undergoing elective major abdominal surgery, with anticipated duration  $\geq 2$ h. Patients on immunosuppressive or antibiotic treatments before surgery were excluded.

**Results:** The level of serum albumin rapidly dropped after surgery.  $\Delta$ Alb correlated to the mE-PASS score ( $r=0.275$ ,  $p=0.01$ ) and to CRP increase ( $r=0.536$ ,  $p<0.001$ ).  $\Delta$ Alb also correlated to overall complications ( $r=0.485$ ,  $p<0.001$ ), CCI ( $r=0.383$ ,  $p<0.001$ ) and LoS ( $r=0.468$ ,  $p<0.001$ ). A  $\Delta$ Alb  $\geq 10$  g/L yielded a sensitivity of 77.1% and a specificity of 67.2% (AUC: 78.3%) to predict complications. Patients with  $\Delta$ Alb  $\geq 10$ g/l on POD 1 showed a 3 fold increased risk of overall postoperative complications.

### Conclusion:

Early postoperative decrease of serum albumin correlated with the extent of surgery, its metabolic response, and with adverse outcomes such as complications and length of stay. A decreased concentration of serum albumin  $\geq 10$ g/l on POD 1 was associated with a 3-fold increased risk of overall postoperative complications, and may thus be used to identify patients at risk.

## STRENGTHS AND LIMITATIONS OF THE STUDY

- The present study has a prospective design and offers a head-to-head comparison with biomarkers currently used in clinical practice (C-Reactive Protein and Procalcitonin).
- Albumin drop was thoroughly assessed by analyzing its correlation with a comprehensive panel of surrogate markers for surgical trauma and validated scores for outcomes.
- The predictive value of combined biomarkers was not assessed in the present study.
- This study involved a single center and included a training cohort, without validation cohort.



## INTRODUCTION

Abdominal surgery is among the most frequently performed elective surgery<sup>1</sup>. Although surgical and perioperative improvements have reduced postoperative mortality over the last decades, postoperative morbidity has remained high<sup>2</sup>. In addition to the morbidity which patients are exposed to, postoperative complications pose a significant financial burden, while important efforts are currently pursued to reduce health care expenditures<sup>2</sup>.

The magnitude of metabolic stress response mirrors the extent of surgery<sup>3 4</sup> and presumably contributes to the risk of developing postoperative complications<sup>5 6</sup>. Early identification of patients at risk may improve outcomes, since measures to attenuate the surgical stress response and to reduce morbidity exist<sup>7</sup>.

Although C-reactive protein (CRP) and procalcitonin (PCT) have been proposed as predictors for adverse outcomes in colorectal surgery, they both display the critical limitation of slow kinetics<sup>8 9</sup>. Conversely, serum albumin (Alb) is a maintenance protein that is rapidly downregulated by inflammatory signals<sup>4 10</sup>. Preliminary data suggested that Alb level rapidly dropped after surgery and correlated to outcomes in esophageal<sup>11</sup>, oral cancer<sup>12</sup>, abdominal<sup>4</sup>, pancreatic<sup>13</sup>, liver resection<sup>14</sup>/transplant<sup>15</sup> and cardiac<sup>16</sup> surgeries. However, prospective validation is missing and Alb is not used to assess surgical stress or to predict outcomes.

This study aimed to test the hypotheses that early postoperative albumin drop (I) reflects the magnitude of surgical trauma, (II) correlates to established markers of metabolic stress, and (III) predicts postoperative complications.

## METHODS

### Study design and patient groups

This prospective study was conducted at the Department for Visceral Surgery at the University Hospital of Lausanne Switzerland (CHUV) between February and December 2015 (NCT02356484). The study was approved by the Institutional Review Board (N°367/15) and all patients provided written consent prior to surgery. Inclusion criteria were age >18 years, and elective major abdominal surgery - defined as an operative procedure with anticipated duration  $\geq 2$ h<sup>17</sup>. Perioperative care closely adhered to recently published enhanced recovery guidelines (<http://erassociety.org.loopiadns.com/guidelines/list-of-guidelines>). Standardized fluid administration was followed by advanced hemodynamic monitoring to avoid intraoperative fluid overload. According to the clinical care pathway, intravenous fluid was typically discontinued the morning after surgery.

Demographics, comorbidities, surgical details and clinical outcomes were prospectively collected and anonymized in a computerized protected database. A two-sample t-test was used to calculate sample size, with size effect of 0.8, power of 0.99 and significance level of 0.05. This determined a required number of 50 patients per group (i.e. with complication vs. without complication). Anticipating a complication rate of 40%, the final sample size for this study was n=125 patients. In order to adjust for 10% drop-out or missing data, final sample size resulted in n=138.

### Extent of surgery

The amplitude of surgical stress was measured by the *Modified Estimation of Physiologic Ability and Surgical Stress* (mE-PASS). Briefly, mE-PASS score encompasses 7 items (6 preoperative variables and the surgical procedure). It predicts the in-hospital mortality and the 30-day mortality rates, respectively<sup>18</sup>. Type of surgery, operative time, and surgical approach (open vs. laparoscopic) were recorded. Conversions from laparoscopy to laparotomy were counted as

1  
2 laparoscopic cases. Anesthesiologists and surgeons jointly estimated blood loss by measuring the  
3  
4 volume of aspirated fluid and soaked gauzes.  
5  
6  
7

### 8 9 **Biological markers**

10  
11 Serum levels of albumin, CRP, PCT and lactate (LCT) were perioperatively measured in a  
12  
13 fasting state, following standardized institutional guidelines. Blood samples were drawn the day  
14  
15 before surgery, the day of surgery (4-6 hours after the end of the operation) and on the first, second  
16  
17 and third postoperative day. As baseline values tend to show large variations especially for  
18  
19 albumin<sup>4 10</sup>, we considered that a dynamic value (difference between two time-points) might be  
20  
21 more informative than a snapshot value. Several values based on pre- and post-operative  
22  
23 concentrations, were thus calculated for each marker (i.e.,  $\Delta$  Max: Maximal difference between the  
24  
25 pre- and post-operative values;  $\Delta$  POD 0: Difference of concentration on POD -1 and POD 0;  $\Delta$   
26  
27 POD 1: Difference of concentration on POD -1 and POD 1).  
28  
29  
30  
31  
32

### 33 34 **Outcome measures**

35  
36 Complications were graded with the Clavien classification within 30 postoperative days,  
37  
38 counting grade I/II events as minor complications and grade III-V as major complications<sup>19</sup>. Every  
39  
40 complication was documented. Global morbidity for each patient was quantified by the  
41  
42 Comprehensive Complication Index (CCI) on a scale from 0 to 100<sup>20</sup>, representing respectively no  
43  
44 complication and postoperative death. Length of stay (LoS) was considered as the duration from  
45  
46 the day of surgery until discharge.  
47  
48  
49  
50

### 51 52 **Statistical analysis**

53  
54 Continuous variables were presented as mean with standard deviation (SD) or median value  
55  
56 with interquartile range (IQR) depending on the normality of the distribution and compared using  
57  
58 Student's *t* test and Mann-Whitney U test, whereas categorical variables were given as frequencies  
59  
60

1  
2 with percentages and compared with chi-square test. For statistical analyses, the following  
3  
4 parameters were dichotomized: age ( $\geq 70$  years), body-mass index ( $\geq 25$  kg/m<sup>2</sup>), operative time  
5  
6 ( $\geq 180$  minutes), and blood loss ( $\geq 200$  ml). Spearman's and Pearson's tests were used to measure  
7  
8 correlations of categorical ( $\rho$ ) and continuous ( $r$ ) variables, respectively. Receiver operating  
9  
10 characteristic (ROC) curves were applied to obtain the area under the curve (AUC), and to  
11  
12 determine ideal cut-offs. Logistic regression was applied to identify independent predictors;  
13  
14 variables with significance  $< 0.1$  in univariable analyses were further included in multivariable  
15  
16 analyses. A p value  $< 0.05$  was considered to be statistically significant in all tests. Data analyses  
17  
18 were generated using SPSS v20 statistical software (Chicago, IL).  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

### Patients Characteristics, Details of Surgery, and Outcomes

During the study period, 155 consecutive patients undergoing major abdominal surgery were potentially eligible for inclusion, but 17 of them refused to participate. As a result, 138 patients were included in the study and had a complete follow-up. Demographics and surgical details are displayed in **Table 1**. Median mE-PASS score was 0.66 (IQR 0.45-0.96).

Overall, 60/138 patients (43%) experienced at least one complication, and one patient died after total gastrectomy and splenopancreatectomy due to cardiorespiratory arrest. Minor and major complications were observed in 35 and 25 patients, respectively. Patients showed a mean CCI of 13.2 (SD 18.5), and were discharged after a median LoS of 8 days (IQR 5-15 days).

### Perioperative Profile of Biomarkers

The perioperative profile of albumin showed a rapid drop induced by surgery, followed by a plateau phase between POD 0 and POD 3 (**Supplementary Figure 1**). Lactate levels peaked in the first 4-6h after surgery and were back to baseline on POD1. Conversely, CRP and PCT showed slow kinetics reaching maximal values on POD 4 and 3, respectively. The mean maximal decrease of albumin was 11.3 g/L ( $\pm$  5.6), which was similar to albumin drop on POD 1: 10.1 g/L (SD: 5.8). Further analyses were hence focused on  $\Delta$ Alb on POD1.

### Correlation of $\Delta$ Alb to surgical stress, biomarkers, and outcomes

$\Delta$ Alb on POD1 correlated to surgical stress (mE-PASS) ( $r=0.275$ ,  $p=0.01$ ) and to surrogates such as duration of surgery ( $r=0.562$ ,  $p<0.001$ ), blood loss ( $r=0.391$ ,  $p<0.001$ ), and surgical approach ( $\rho=0.55$ ,  $p<0.001$ ) (**Figure 1**).

$\Delta$ Alb on POD1 also correlated to maximal increases of CRP ( $r=0.54$ ,  $p<0.001$ ), PCT ( $r=0.43$ ,  $p<0.001$ ), and LCT ( $r=0.25$ ,  $p=0.02$ ). Furthermore, a positive and significant correlation was highlighted between  $\Delta$ Alb on POD1 and  $\Delta$ CRP on POD4 ( $\rho=0.234$ ,  $p=0.044$ ).  $\Delta$ Alb on POD1 was



## DISCUSSION

Surgery induced a rapid decrease of serum albumin in patients undergoing elective major abdominal procedures; and it remained stable for several postoperative days. Although correlation coefficients were modest, the decrease in serum albumin significantly correlated with (I) the extent of surgery (mE-PASS, blood loss, duration of surgery, and surgical approach), (II) the maximal amplitude of other stress markers, such as CRP, PCT and LCT and (III) was consistently associated with adverse outcomes (according to both Clavien classification, CCI, and LoS). A serum albumin decrease  $\geq 10$  g/L on POD 1 was independently associated with a 3-fold increased risk for postoperative complication.

The present study tested a panel of 4 biomarkers of which 2 are routinely used and served as benchmarks (CRP and PCT) and 2 are less established markers and deserved prospective investigations (Alb and LCT). The mE-PASS accurately recapitulates surgical stress, and was validated and used in abdominal surgery<sup>18 21-24</sup>. To our knowledge, there is no other validated and available score. One study endpoint was the CCI, which is a score summing each complication graded according to the Clavien classification. As a result, CCI avoids omitting minor complications, and is therefore more accurate than the Clavien classification alone<sup>20</sup>. Serum albumin showed the more consistent correlation with stress response and clinical outcomes. Alb and LCT both display some of the features for ideal markers: easy to measure and to interpret, readily available, can be repeated for monitoring and non-expensive. While Alb rapidly dropped after surgery and subsequently stabilized until POD 3, lactate showed a prompt increase followed by a fast return to baseline value, already on POD 1. It can be assumed that the timing of blood collection may have a more important impact on LCT than on Alb. As a consequence, Alb is more robust and easier used in the clinical setting. Importantly, the selected markers were repeatedly measured, which allowed us to capture their perioperative profiles and to further calculate differences of concentrations between various time-points. The latter was revealed to be pivotal and more informative than a single value.

1  
2 The mechanisms of early postoperative albumin decrease combine altered metabolism,  
3 blood loss/dilution and most importantly redistribution into the third space, due to capillary  
4 leakage. The latter accounts for >75% of albumin decrease in the early postoperative phase and  
5  
6  
7  
8  
9 appears to be related to the magnitude of systemic inflammatory response<sup>10 25 26</sup>. Therefore,  
10  
11 albumin decrease is certainly influenced by perioperative fluid management (liberal vs. restrictive)  
12  
13  
14 but it mainly reflects the extent of postsurgical stress response.

15  
16 In multivariable analysis (table 2), 2 factors were independently associated with  
17  
18 complications: approach and  $\Delta\text{Alb POD1} \geq 10$  g/L. The overlap of certain parameters of surgical  
19  
20 stress may, in part, explain why they were not identified as independent predictors of  
21  
22 complications. It may also suggest that serum albumin mirrors these different parameters.  
23

24  
25 Some limitations need to be addressed. The present analyses were focused on 4 biomarkers  
26  
27 that are readily available and easy to evaluate in the clinical setting. This non-inclusive panel of  
28  
29 biomarkers could be perceived as a methodological shortcoming. Notwithstanding, integrating  
30  
31 more complex and costly biomarkers would unlikely be more informative given their poor  
32  
33 reproducibility, cost and assay measurement complexity. Likewise, this study did not assess the  
34  
35 predictive value of albumin drop combined with other biomarker and/or clinical variables.  
36  
37 Although such a classifier may presumably improve sensitivity and specificity, it will also be more  
38  
39 complex which could ultimately preclude its implementation in clinical practice. Blood collection  
40  
41 on POD 0 occurred 4-6 hours after the end of surgery. This delay might be long enough to alter the  
42  
43 discriminatory ability of certain biomarkers, particularly lactate<sup>27</sup>. Finally, the present findings  
44  
45 need to be further validated with an independent cohort.  
46  
47  
48

49 Available data on the predictive role of postoperative Alb are scarce; and most of these  
50  
51 reports were retrospective studies<sup>11-13 16 28</sup>. Of note, each of the studies investigated only a single  
52  
53 postoperative value of serum albumin. This represents a critical drawback as it cannot be  
54  
55 discerned whether the low postoperative concentration of serum albumin resulted from intense  
56  
57 surgical stress or from low preoperative level, which is an acknowledged predictor of increased  
58  
59  
60



1  
2 postoperative complication<sup>29 30</sup>. A prospective pilot study in abdominal surgery – conducted  
3 recently in our institution- showed consistent findings, with an increased risk of complication  
4 related to the amplitude of serum albumin postoperative drop<sup>4</sup>. Of note, the cohorts from this  
5 previous study (70 patients) and from the present one (138 patients) were strictly distinct.  
6  
7  
8  
9  
10  
11 Postoperative lactate has been more thoroughly explored in liver surgery, with few reports in other  
12 surgical fields. In a recent landmark study, Vibert et al. demonstrated that a postoperative cut-off  
13 of arterial lactate > 3mmol/L at the end of surgery was an independent predictor of complications  
14 after elective hepatectomies<sup>27</sup>. Their conclusion correlates with the present findings since  $\Delta$ LCT  
15 POD0 was correlated with mE-PASS (p=0.039), overall complication (p<0.001), CCI (p=0.007)  
16 and LoS (p=0.008) (**Figure 2**). Although both CRP and PCT are routinely used biomarkers in  
17 clinical practice, they are typically contributive on POD 4 only. The present study design allowed  
18 to confirm the ultimate advantage of Alb to be up-regulated within the early postoperative phase,  
19 illustrated by the correlation between  $\Delta$ Alb on POD1 and  $\Delta$ CRP on POD4 ( $\rho=0.234$ ,  $p=0.044$ ),  
20 highlighted in this study. In fact,  $\Delta$ Alb on POD1 was more sensitive than  $\Delta$ CRP on POD4,  
21 illustrated by AUC of 0.78 and 0.75, respectively (Figure 3 and Supplementary 3D).  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 How the monitoring of Alb in surgical patients can lead to better outcomes is a key  
37 question. Measures to preoperatively attenuate the stress response to surgery have been extensively  
38 explored. Interestingly, successful attempts were reported with immunonutrition<sup>31</sup>, enhanced  
39 recovery programs (ERAS)<sup>32 33</sup>, or high-dose glucocorticoids<sup>34</sup>. Whether these options would be  
40 able to restrain the stress response, once triggered, in the early postoperative phase remains to be  
41 investigated. In this setting, albumin drop may indicate whether these measures may be beneficial  
42 in the perioperative period by being incorporated into the design of clinical trials as a marker for  
43 patients at higher risk of perioperative complications.  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 In summary, early postoperative decrease of serum albumin correlated with the (I)  
54 extent of surgery, (II) its metabolic response, and with (III) adverse outcomes such as  
55 complications and length of hospital stay. A decreased concentration of serum albumin  $\geq 10$ g/l on  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

POD 1 was associated with a 3-fold increased risk of overall postoperative complications; albumin decrease occurs rapidly after surgery and remains stable for several days. As it is easy to measure, it could be used to identify patients at risk.

For peer review only

**REFERENCES**

1. Noordzij PG, Poldermans D, Schouten O, et al. Postoperative mortality in The Netherlands: a population-based analysis of surgery-specific risk in adults. *Anesthesiology* 2010;**112**(5):1105-15.
2. Vonlanthen R, Slankamenac K, Breitenstein S, et al. The impact of complications on costs of major surgical procedures: a cost analysis of 1200 patients. *Ann Surg* 2011;**254**(6):907-13.
3. Thorell A, Nygren J, Ljungqvist O. Insulin resistance: a marker of surgical stress. *Curr Opin Clin Nutr Metab Care* 1999;**2**(1):69-78.
4. Mantziari S, Hubner M, Coti-Bertrand P, et al. A Novel Approach to Major Surgery: Tracking Its Pathophysiologic Footprints. *World J Surg* 2015;**39**(11):2641-51.
5. Kohl BA, Deutschman CS. The inflammatory response to surgery and trauma. *Curr Opin Crit Care* 2006;**12**(4):325-32.
6. Amar D, Zhang H, Park B, et al. Inflammation and outcome after general thoracic surgery. *Eur J Cardiothorac Surg* 2007;**32**(3):431-4.
7. Hall R. Identification of inflammatory mediators and their modulation by strategies for the management of the systemic inflammatory response during cardiac surgery. *J Cardiothorac Vasc Anesth* 2013;**27**(5):983-1033.
8. Facy O, Paquette B, Orry D, et al. Diagnostic Accuracy of Inflammatory Markers As Early Predictors of Infection After Elective Colorectal Surgery: Results From the IMACORS Study. *Ann Surg* 2016;**263**(5):961-6.
9. Giaccaglia V, Salvi PF, Antonelli MS, et al. Procalcitonin Reveals Early Dehiscence in Colorectal Surgery: The PREDICS Study. *Ann Surg* 2016;**263**(5):967-72.
10. Hubner M, Mantziari S, Demartines N, et al. Postoperative Albumin Drop Is a Marker for Surgical Stress and a Predictor for Clinical Outcome: A Pilot Study. *Gastroenterol Res Pract* 2016;**2016**:8743187.

- 1  
2 11. Ryan AM, Hearty A, Prichard RS, et al. Association of hypoalbuminemia on the first  
3  
4 postoperative day and complications following esophagectomy. *J Gastrointest Surg*  
5  
6 2007;**11**(10):1355-60.  
7  
8
- 9 12. Lee JI, Kwon M, Roh JL, et al. Postoperative hypoalbuminemia as a risk factor for surgical site  
10  
11 infection after oral cancer surgery. *Oral Dis* 2015;**21**(2):178-84.  
12
- 13 13. Fujiwara Y, Shiba H, Shirai Y, et al. Perioperative serum albumin correlates with postoperative  
14  
15 pancreatic fistula after pancreaticoduodenectomy. *Anticancer Res* 2015;**35**(1):499-503.  
16
- 17 14. Labgaa I, Joliat GR, Demartines N, et al. Serum albumin is an early predictor of complications  
18  
19 after liver surgery. *Dig Liver Dis* 2016;**48**(5):559-61.  
20
- 21 15. Sang BH, Bang JY, Song JG, et al. Hypoalbuminemia Within Two Postoperative Days Is an  
22  
23 Independent Risk Factor for Acute Kidney Injury Following Living Donor Liver  
24  
25 Transplantation: A Propensity Score Analysis of 998 Consecutive Patients. *Crit Care Med*  
26  
27 2015;**43**(12):2552-61.  
28
- 29 16. Lee EH, Chin JH, Choi DK, et al. Postoperative hypoalbuminemia is associated with outcome  
30  
31 in patients undergoing off-pump coronary artery bypass graft surgery. *J Cardiothorac Vasc*  
32  
33 *Anesth* 2011;**25**(3):462-8.  
34  
35
- 36 17. Hubner M, Cerantola Y, Grass F, et al. Preoperative immunonutrition in patients at nutritional  
37  
38 risk: results of a double-blinded randomized clinical trial. *Eur J Clin Nutr* 2012;**66**(7):850-  
39  
40 5.  
41  
42
- 43 18. Haga Y, Ikejiri K, Wada Y, et al. A multicenter prospective study of surgical audit systems.  
44  
45 *Ann Surg* 2011;**253**(1):194-201.  
46  
47
- 48 19. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal  
49  
50 with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg*  
51  
52 2004;**240**(2):205-13.  
53  
54
- 55 20. Slankamenac K, Graf R, Barkun J, et al. The comprehensive complication index: a novel  
56  
57 continuous scale to measure surgical morbidity. *Ann Surg* 2013;**258**(1):1-7.  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
21. Haga Y, Ikejiri K, Takeuchi H, et al. Value of general surgical risk models for predicting postoperative liver failure and mortality following liver surgery. *J Surg Oncol* 2012;**106**(7):898-904.
22. Haga Y, Wada Y, Takeuchi H, et al. Evaluation of modified Estimation of Physiologic Ability and Surgical Stress in gastric carcinoma surgery. *Gastric Cancer* 2012;**15**(1):7-14.
23. Haga Y, Wada Y, Takeuchi H, et al. Evaluation of modified estimation of physiologic ability and surgical stress in patients undergoing surgery for choledochocystolithiasis. *World J Surg* 2014;**38**(5):1177-83.
24. Haga Y, Wada Y, Saitoh T, et al. Value of general surgical risk models for predicting postoperative morbidity and mortality in pancreatic resections for pancreatobiliary carcinomas. *J Hepatobiliary Pancreat Sci* 2014;**21**(8):599-606.
25. Smeets HJ, Kievit J, Dulfer FT, et al. Analysis of post-operative hypalbuminaemia: a clinical study. *Int Surg* 1994;**79**(2):152-7.
26. Fleck A, Raines G, Hawker F, et al. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. *Lancet* 1985;**1**(8432):781-4.
27. Vibert E, Boleslawski E, Cosse C, et al. Arterial Lactate Concentration at the End of an Elective Hepatectomy Is an Early Predictor of the Postoperative Course and a Potential Surrogate of Intraoperative Events. *Ann Surg* 2015;**262**(5):787-93.
28. Sang BH, Bang JY, Song JG, et al. Hypoalbuminemia Within Two Postoperative Days Is an Independent Risk Factor for Acute Kidney Injury Following Living Donor Liver Transplantation: A Propensity Score Analysis of 998 Consecutive Patients. *Crit Care Med* 2015.
29. Poon RT, Fan ST, Lo CM, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. *Ann Surg* 2004;**240**(4):698-708; discussion 08-10.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
30. Uzunoglu FG, Reeh M, Vettorazzi E, et al. Preoperative Pancreatic Resection (PREPARE) score: a prospective multicenter-based morbidity risk score. *Ann Surg* 2014;**260**(5):857-63; discussion 63-4.
31. Cerantola Y, Hubner M, Grass F, et al. Immunonutrition in gastrointestinal surgery. *Br J Surg* 2011;**98**(1):37-48.
32. Carli F. Physiologic considerations of Enhanced Recovery After Surgery (ERAS) programs: implications of the stress response. *Can J Anaesth* 2015;**62**(2):110-9.
33. Ljungqvist O, Nygren J, Soop M, et al. Metabolic perioperative management: novel concepts. *Curr Opin Crit Care* 2005;**11**(4):295-9.
34. de la Motte L, Kehlet H, Vogt K, et al. Preoperative methylprednisolone enhances recovery after endovascular aortic repair: a randomized, double-blind, placebo-controlled clinical trial. *Ann Surg* 2014;**260**(3):540-8; discussion 48-9.

**Table 1: Baseline characteristics of patients with and without postoperative complications.**

|                                  | Pat. with<br>complications<br>(n=60)<br>n (%) | Pat. without<br>complications<br>(n=78)<br>n (%) | p-value       |        |
|----------------------------------|---|--|---------------|--------|
| <b>Demographics</b>              |   |  |               |        |
| Median age (years)*              | 64 (50-73)                                    | 59 (51-69)                                       | 0.306         |        |
| Age ≥ 70 years                   | 20 (51)                                       | 19 (49)  | 0.246         |        |
| Gender (male)                    | 38 (63)                                       | 34 (44)  | <b>0.021</b>  |        |
| Median BMI (kg/m <sup>2</sup> )* | 24 (22-28)                                    | 26 (22-31)                                       | <b>0.038</b>  |        |
| BMI ≥25 kg/m <sup>2</sup>        | 27 (47)                                       | 46 (60)  | 0.128         |        |
| <b>Comorbidities</b>             |   |  |               |        |
| ASA (I-II)                       | 36 (60)                                       | 52 (67)  | 0.419         |        |
| ECOG (0-1)                       | 45 (75)                                       | 66 (85)  | 0.158         |        |
| Cirrhosis                        | 2 (3)   | 1 (1)  | 0.413         |        |
| Heart disease                    | 10 (17)                                       | 12 (16)  | 0.864         |        |
| Lung disease                     | 8 (13)  | 7 (9)  | 0.415         |        |
| Diabetes                         | 8 (13)  | 13 (17)  | 0.589         |        |
| History of surgery               | 33 (55)                                       | 42 (55)  | 0.958         |        |
| Cancer                           | 45 (75)                                       | 54 (69)  | 0.456         |        |
| <b>Surgery</b>                   |   |  |               |        |
| <b>Type</b>                      |   |  |               |        |
|                                  | Colorectal                                    | 14 (23)  | 17 (22)       | 0.840  |
|                                  | HPB   | 31 (52)  | 19 (24)       | 0.001  |
|                                  | Upper-GI                                      | 11 (18)  | 17 (22)       | 0.674  |
|                                  | Other   | 4 (7)  | 25 (32)       | <0.001 |
| <b>Approach</b>                  |   |  |               |        |
|                                  | Open  | 50 (83)  | 29 (37)       |        |
|                                  | Laparoscopy                                   | 10 (17)  | 49 (63)       |        |
| <b>Duration</b>                  |   |  |               |        |
|                                  | Median (min)*                                 | 271 (224-340)                                    | 154 (112-239) | <0.001 |
|                                  | ≥ 180 min                                     | 46 (77)  | 33 (42)       | <0.001 |
| <b>Blood Loss</b>                |   |  |               |        |
|                                  | Median (mL)*                                  | 300 (100-575)                                    | 90 (0-263)    | 0.002  |
|                                  | ≥ 200 mL                                      | 40 (67)  | 24 (31)       | <0.001 |
| Intravenous fluid (mL)           | 2500 (2000-4000)                              | 1500 (1000-2500)                                 | 0.018         |        |
| Median mE-PASS                   | 0.77 (0.57-1.03)                              | 0.49 (0.4-0.81)                                  | 0.12          |        |

BMI: Body mass index; ASA: American Association of Anesthesiologists physical status classification system; ECOG: Eastern Cooperative Oncology Group performance status; cancer: operative indication; HPB: Hepato-Pancreatico-Biliary surgery; Upper-GI: Upper-Gastrointestinal surgery; mE-PASS: Modified Estimation of Physiologic Ability and Surgical Stress; CCI: Comprehensive complication index; LoS: Length of stay. Other surgeries included pressurized intra-abdominal aerosol chemotherapy (17), endocrine operations (4), complex abdominal wall operations (2), resections of retroperitoneal sarcomas (3), nephrectomy (1), and interrupted limb perfusions for melanoma (2). \* Median values (IQR)

**Table 2: Logistic regression with uni- and multivariable analysis for predictors of postoperative complications.**

|                                 | Overall postoperative complications |            |                  |               |            |              |
|---------------------------------|-------------------------------------|------------|------------------|---------------|------------|--------------|
|                                 | Univariable                         |            |                  | Multivariable |            |              |
|                                 | OR                                  | 95% CI     | p-value          | OR            | 95% CI     | p-value      |
| Age $\geq$ 70 years             | 1.55                                | 0.74-3.27  | 0.247            |               |            |              |
| Gender (Female)                 | 0.45                                | 0.22-0.89  | <b>0.022</b>     | 1.06          | 0.38-2.96  | 0.905        |
| ASA I/II                        | 1.33                                | 0.66-2.68  | 0.42             |               |            |              |
| ECOG 0/1                        | 1.83                                | 0.79-4.28  | 0.161            |               |            |              |
| Cirrhosis                       | 2.66                                | 0.24-30    | 0.43             |               |            |              |
| Cancer                          | 1.33                                | 0.63-2.84  | 0.456            |               |            |              |
| Diabetes                        | 0.77                                | 0.3-2      | 0.59             |               |            |              |
| BMI $\geq$ 25 kg/m <sup>2</sup> | 0.59                                | 0.3-1.17   | 0.129            |               |            |              |
| Approach (open)                 | 8.49                                | 3.72-19.18 | <b>&lt;0.001</b> | 11.22         | 2.74-46.05 | <b>0.001</b> |
| Duration $\geq$ 180 min         | 4.48                                | 2.12-9.47  | <b>&lt;0.001</b> | 0.47          | 0.11-1.94  | 0.297        |
| Blood loss $\geq$ 200 mL        | 4.50                                | 2.19-9.25  | <b>&lt;0.001</b> | 1.68          | 0.57-4.99  | 0.350        |
| $\Delta$ Alb POD1 $\geq$ 10 g/L | 6.89                                | 2.94-16.14 | <b>&lt;0.001</b> | 3.29          | 1.14-9.49  | <b>0.028</b> |

ASA: American Association of Anesthesiologists physical status classification system; ECOG: Eastern Cooperative Oncology Group performance status; BMI: Body mass index;  $\Delta$ Alb POD1: The difference between serum albumin concentration on POD -1 and POD 1 (g/L). OR: odds ratio



## LEGENDS

### Figure 1:

$\Delta$ Alb on POD1 correlates with the extent of surgery.  $\Delta$ Alb on POD1 showed a significant correlation with (a) mE-PASS ( $r=0.275$ ,  $p=0.01$ ), (b) blood loss ( $r=0.391$ ,  $p<0.001$ ), and (c) duration of surgery ( $r=0.562$ ,  $p<0.001$ ).

### Figure 2:

The postoperative decrease of Alb on POD 1 correlated with outcomes.  $\Delta$ Alb on POD1 showed a significant correlation with CCI (Comprehensive complication index) (a), and with length of stay (LoS) (b).

### Figure 3:

Receiver operating characteristic (ROC) curve to determine the optimal cut-off of  $\Delta$ Alb on POD1 (blue line), showed an AUC of 0.78.

### Supplementary Figure 1:

Mean perioperative concentration of serum albumin (vertical bars illustrate standard deviations).

### Supplementary Figure 2:

$\Delta$ CRP (a),  $\Delta$ PCT (b) and  $\Delta$ LCT (c) on POD1 yielded AUC of 0.73, 0.63 and 0.64, respectively. The AUC of  $\Delta$ CRP on POD4 was 0.75 (d).

**Contributorship statement:**

IL involved in study design, data collection, analysis and interpretation, review of the literature, drafting and critical revision of the manuscript. GRJ involved in study design, data collection, analysis and interpretation, review of the literature, critical revision of the manuscript. AK involved in data collection, analysis and interpretation, review of the literature, critical revision of the manuscript. SM involved in data collection, analysis and interpretation, review of the literature, critical revision of the manuscript. MS involved in study design, analysis and interpretation, critical revision of the manuscript. ND involved in study design, analysis and interpretation, critical revision of the manuscript. MH study design, analysis and interpretation, drafting and critical revision of the manuscript.

**Competing interests:** There are no conflicts of interest relevant to the nature of this manuscript.

**Sources of funding:** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors

**Data sharing statement:** There is no additional data.

Figure 1: The Intensity of  $\Delta$ Alb on POD1 Correlates With the Extent of Surgery




Figure 1

254x190mm (300 x 300 DPI)

ew only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 2:  $\Delta$ Alb on POD1 Correlates With Complications (CCI) and Length of Stay (LoS)




Figure 2

254x190mm (300 x 300 DPI)

ew only

Figure 3: Receiver operating characteristic (ROC) curve of  $\Delta$ Alb on POD1





Figure 3

254x190mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


**Supplementary Figure 1: Perioperative Kinetics of Serum Albumin (Alb)**



254x190mm (300 x 300 DPI)

ew only

Supplementary Figure 2: Receiver operating characteristic (ROC) curves of other stress markers



254x190mm (300 x 300 DPI)

ew only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Supplementary Table 1: Correlations of the candidate biomarkers with outcomes.

|            |         | mE-PASS |                  | Minor (I-II) |              | Major (III-V) |                  | Overall complication |                  | CCI     |                  | LoS     |                  |
|------------|---------|---------|------------------|--------------|--------------|---------------|------------------|----------------------|------------------|---------|------------------|---------|------------------|
|            |         | Pearson | p-value          | Spearman     | p-value      | Spearman      | p-value          | Spearman             | p-value          | Pearson | p-value          | Pearson | p-value          |
| <b>CRP</b> | Δ Max   | 0.062   | 0.530            | 0.256        | <b>0.003</b> | 0.387         | <b>&lt;0.001</b> | 0.534                | <b>&lt;0.001</b> | 0.529   | <b>&lt;0.001</b> | 0.484   | <b>&lt;0.001</b> |
|            | Δ POD 0 | 0.052   | 0.693            | 0.070        | 0.566        | 0.049         | 0.686            | 0.098                | 0.417            | 0.231   | 0.052            | 0.381   | <b>0.001</b>     |
|            | Δ POD 1 | 0.116   | 0.256            | 0.207        | <b>0.024</b> | 0.273         | <b>0.003</b>     | 0.395                | <b>&lt;0.001</b> | 0.469   | <b>&lt;0.001</b> | 0.462   | <b>&lt;0.001</b> |
| <b>Alb</b> | Δ Max   | 0.323   | <b>0.001</b>     | 0.264        | <b>0.003</b> | 0.345         | <b>&lt;0.001</b> | 0.470                | <b>&lt;0.001</b> | 0.373   | <b>&lt;0.001</b> | 0.358   | <b>&lt;0.001</b> |
|            | Δ POD 0 | 0.479   | <b>&lt;0.001</b> | 0.298        | <b>0.006</b> | 0.194         | 0.077            | 0.420                | <b>&lt;0.001</b> | 0.302   | <b>0.005</b>     | 0.259   | <b>0.018</b>     |
|            | Δ POD 1 | 0.275   | <b>0.010</b>     | 0.228        | <b>0.016</b> | 0.372         | <b>&lt;0.001</b> | 0.485                | <b>&lt;0.001</b> | 0.383   | <b>&lt;0.001</b> | 0.468   | <b>&lt;0.001</b> |
| <b>PCT</b> | Δ Max   | -0.050  | 0.656            | 0.240        | <b>0.016</b> | 0.181         | 0.071            | 0.339                | <b>0.001</b>     | 0.140   | 0.162            | 0.204   | <b>0.040</b>     |
|            | Δ POD 0 | 0.017   | 0.906            | 0.171        | 0.204        | 0.076         | 0.570            | 0.211                | 0.112            | 0.015   | 0.909            | 0.168   | 0.206            |
|            | Δ POD 1 | -0.010  | 0.933            | 0.135        | 0.216        | 0.150         | 0.165            | 0.220                | <b>0.041</b>     | -0.034  | 0.752            | 0.103   | 0.342            |
| <b>LCT</b> | Δ Max   | 0.269   | <b>0.013</b>     | 0.301        | <b>0.003</b> | 0.196         | 0.057            | 0.426                | <b>&lt;0.001</b> | 0.317   | <b>0.002</b>     | 0.327   | <b>0.001</b>     |
|            | Δ POD 0 | 0.244   | <b>0.039</b>     | 0.297        | <b>0.007</b> | 0.178         | 0.111            | 0.412                | <b>&lt;0.001</b> | 0.299   | <b>0.007</b>     | 0.292   | <b>0.008</b>     |
|            | Δ POD 1 | 0.118   | 0.331            | 0.265        | <b>0.018</b> | 0.026         | 0.817            | 0.248                | <b>0.026</b>     | 0.193   | 0.087            | 0.104   | 0.360            |

Complications are graded according to the Clavien classification (grade I to V); mE-PASS: Modified Estimation of Physiologic Ability and Surgical Stress; CCI: Comprehensive complication index; LoS: Length of stay; CRP: C-reactive protein; Alb: Serum albumin; PCT: Procalcitonin; LCT: Lactates; Δ Max: Maximal difference between the pre- and post-operative values; Δ POD 0: Difference of concentration on POD -1 and POD 0; Δ Pod 1: Difference of concentration on POD -1 and POD 1



Supplementary Table 2: Discriminatory ability of albumin decrease on POD1

|                      | $\Delta$ Alb POD1 |               | p-value          |
|----------------------|-------------------|---------------|------------------|
|                      | <10 g/L           | $\geq$ 10 g/L |                  |
|                      | n (%)             | n (%)         |                  |
| <b>Complications</b> |                   |               |                  |
| Minor (I-II)         | 8 (15)            | 21 (36)       | <b>0.011</b>     |
| Major (III-V)        | 3 (6)             | 16 (28)       | <b>0.002</b>     |
| Overall              | 11 (20)           | 37 (64)       | <b>&lt;0.001</b> |
| CCI                  | 0                 | 20.9 (0-33.5) | <b>&lt;0.001</b> |
| <b>LoS</b>           | 4 (4-7)           | 13 (13-21)    | <b>&lt;0.001</b> |

Complications are graded according to the Clavien classification (grade I to V);  $\Delta$ Alb POD1: The difference between serum albumin concentration on POD -1 and POD 1 (g/L); mE-PASS: Modified Estimation of Physiologic Ability and Surgical Stress; CCI: Comprehensive complication index; LoS: Length of stay

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

| Section/Topic                | Item # | Recommendation   | Reported on page # |
|------------------------------|--------|--|--------------------|
| Title and abstract           | 1      | (a) Indicate the study's design with a commonly used term in the title or the abstract   | 1                  |
|                              |        | (b) Provide in the abstract an informative and balanced summary of what was done and what was found  | 2                  |
| <b>Introduction</b>          |        |  |                    |
| Background/rationale         | 2      | Explain the scientific background and rationale for the investigation being reported   | 4                  |
| Objectives                   | 3      | State specific objectives, including any prespecified hypotheses   | 4                  |
| <b>Methods</b>               |        |  |                    |
| Study design                 | 4      | Present key elements of study design early in the paper  | 5                  |
| Setting                      | 5      | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection  | 5                  |
| Participants                 | 6      | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up   | 5                  |
|                              |        | (b) For matched studies, give matching criteria and number of exposed and unexposed  | Not applicable     |
| Variables                    | 7      | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable   | 5-6                |
| Data sources/<br>measurement | 8*     | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 5-6                |
| Bias                         | 9      | Describe any efforts to address potential sources of bias  | 5-6                |
| Study size                   | 10     | Explain how the study size was arrived at  | 5                  |
| Quantitative variables       | 11     | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why   | 5-6                |
| Statistical methods          | 12     | (a) Describe all statistical methods, including those used to control for confounding  | 6                  |
|                              |        | (b) Describe any methods used to examine subgroups and interactions  | 6                  |
|                              |        | (c) Explain how missing data were addressed  | 6                  |
|                              |        | (d) If applicable, explain how loss to follow-up was addressed   | Not applicable     |
|                              |        | (e) Describe any sensitivity analyses  | 6                  |

|                          |     |  |                |
|--------------------------|-----|--|----------------|
| <b>Results</b>           |     |  |                |
| Participants             | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed            | 7              |
|                          |     | (b) Give reasons for non-participation at each stage   | 7              |
|                          |     | (c) Consider use of a flow diagram   | Not applicable |
| Descriptive data         | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders   | 7              |
|                          |     | (b) Indicate number of participants with missing data for each variable of interest  | 16             |
|                          |     | (c) Summarise follow-up time (eg, average and total amount)  | 8              |
| Outcome data             | 15* | Report numbers of outcome events or summary measures over time   | 7-8            |
| Main results             | 16  | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 8              |
|                          |     | (b) Report category boundaries when continuous variables were categorized  | 6              |
|                          |     | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period   | Not applicable |
| Other analyses           | 17  | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses   | 8              |
| <b>Discussion</b>        |     |  |                |
| Key results              | 18  | Summarise key results with reference to study objectives   | 9              |
| <b>Limitations</b>       |     |  |                |
| Interpretation           | 20  | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence                                   | 10             |
| Generalisability         | 21  | Discuss the generalisability (external validity) of the study results  | 11             |
| <b>Other information</b> |     |  |                |
| Funding                  | 22  | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based  | 20             |

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>